<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PONE-D-10-00565</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0016038</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Immunology</subject>
            <subj-group>
              <subject>Immunity</subject>
              <subj-group>
                <subject>Inflammation</subject>
                <subject>Innate immunity</subject>
              </subj-group>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Model organisms</subject>
            <subj-group>
              <subject>Animal models</subject>
              <subj-group>
                <subject>Mouse</subject>
              </subj-group>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Molecular cell biology</subject>
            <subj-group>
              <subject>Signal transduction</subject>
              <subj-group>
                <subject>Signaling cascades</subject>
                <subj-group>
                  <subject>c-Jun N-terminal kinase signaling cascade</subject>
                </subj-group>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Cellular stress responses</subject>
              <subject>Gene expression</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Neuroscience</subject>
            <subj-group>
              <subject>Molecular neuroscience</subject>
              <subj-group>
                <subject>Signaling pathways</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Neurochemistry</subject>
              <subj-group>
                <subject>Neurochemicals</subject>
                <subj-group>
                  <subject>Dopamine</subject>
                </subj-group>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Neurobiology of disease and regeneration</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Neurology</subject>
            <subj-group>
              <subject>Neurodegenerative diseases</subject>
              <subject>Parkinson disease</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Immunology</subject>
          <subject>Molecular Biology</subject>
          <subject>Cell Biology</subject>
          <subject>Neuroscience</subject>
          <subject>Neurological Disorders</subject>
        </subj-group>
      </article-categories><title-group><article-title>Increased Mitochondrial Calcium Sensitivity and Abnormal Expression of Innate Immunity Genes Precede Dopaminergic Defects in <italic>Pink1</italic>-Deficient Mice</article-title><alt-title alt-title-type="running-head">DA and Mitochondrial Defects in <italic>Pink1<sup>−/−</sup></italic> Mice</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Akundi</surname>
            <given-names>Ravi S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Huang</surname>
            <given-names>Zhenyu</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Eason</surname>
            <given-names>Joshua</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Pandya</surname>
            <given-names>Jignesh D.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Zhi</surname>
            <given-names>Lianteng</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Cass</surname>
            <given-names>Wayne A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Sullivan</surname>
            <given-names>Patrick G.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Büeler</surname>
            <given-names>Hansruedi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Anatomy and Neurobiology, University of Kentucky College of Medicine, Lexington, Kentucky, United States of America</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Spinal Cord and Brain Injury Research Center, University of Kentucky College of Medicine, Lexington, Kentucky, United States of America</addr-line>       </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Cookson</surname>
            <given-names>Mark R.</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">National Institutes of Health, United States of America</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">hansruedi.bueler@uky.edu</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: HB PGS. Performed the experiments: ZH RSA JE JDP LZ WAC. Analyzed the data: HB PGS WAC. Wrote the paper: HB.</p>
        </fn>
      <fn fn-type="conflict">
        <p>The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <year>2011</year>
      </pub-date><pub-date pub-type="epub">
        <day>13</day>
        <month>1</month>
        <year>2011</year>
      </pub-date><volume>6</volume><issue>1</issue><elocation-id>e16038</elocation-id><history>
        <date date-type="received">
          <day>13</day>
          <month>8</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>5</day>
          <month>12</month>
          <year>2010</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Akundi et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
        <sec>
          <title>Background</title>
          <p>PTEN-induced kinase 1 (PINK1) is linked to recessive Parkinsonism (EOPD). <italic>Pink1</italic> deletion results in impaired dopamine (DA) release and decreased mitochondrial respiration in the striatum of mice. To reveal additional mechanisms of <italic>Pink1</italic>-related dopaminergic dysfunction, we studied Ca<sup>2+</sup> vulnerability of purified brain mitochondria, DA levels and metabolism and whether signaling pathways implicated in Parkinson's disease (PD) display altered activity in the nigrostriatal system of <italic>Pink1<sup>−/−</sup></italic> mice.</p>
        </sec>
        <sec>
          <title>Methods and Findings</title>
          <p>Purified brain mitochondria of <italic>Pink1<sup>−/−</sup></italic> mice showed impaired Ca<sup>2+</sup> storage capacity, resulting in increased Ca<sup>2+</sup> induced mitochondrial permeability transition (mPT) that was rescued by cyclosporine A. A subpopulation of neurons in the substantia nigra of <italic>Pink1<sup>−/−</sup></italic> mice accumulated phospho-c-Jun, showing that Jun N-terminal kinase (JNK) activity is increased. <italic>Pink1<sup>−/−</sup></italic> mice 6 months and older displayed reduced DA levels associated with increased DA turnover. Moreover, <italic>Pink1<sup>−/−</sup></italic> mice had increased levels of IL-1β, IL-12 and IL-10 in the striatum after peripheral challenge with lipopolysaccharide (LPS), and <italic>Pink1<sup>−/−</sup></italic> embryonic fibroblasts showed decreased basal and inflammatory cytokine-induced nuclear factor kappa-β (NF-κB) activity. Quantitative transcriptional profiling in the striatum revealed that <italic>Pink1<sup>−/−</sup></italic> mice differentially express genes that (i) are upregulated in animals with experimentally induced dopaminergic lesions, (ii) regulate innate immune responses and/or apoptosis and (iii) promote axonal regeneration and sprouting.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Increased mitochondrial Ca<sup>2+</sup> sensitivity and JNK activity are early defects in <italic>Pink1<sup>−/−</sup></italic> mice that precede reduced DA levels and abnormal DA homeostasis and may contribute to neuronal dysfunction in familial PD. Differential gene expression in the nigrostriatal system of <italic>Pink1<sup>−/−</sup></italic> mice supports early dopaminergic dysfunction and shows that <italic>Pink1</italic> deletion causes aberrant expression of genes that regulate innate immune responses. While some differentially expressed genes may mitigate neurodegeneration, increased LPS-induced brain cytokine expression and impaired cytokine-induced NF-κB activation may predispose neurons of <italic>Pink1<sup>−/−</sup></italic> mice to inflammation and injury-induced cell death.</p>
        </sec>
      </abstract><funding-group><funding-statement>This work was supported in part by a COBRE grant (P20 RR15592) from the National Center for Research Resources (NCRR), as well as by grants from Parkinson Schweiz and the American Parkinson's Disease Association (APDA) to H.B. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
        <page-count count="17"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Mutations in the <italic>PARK6</italic> gene encoding PINK1 are the second most frequent cause for EOPD <xref ref-type="bibr" rid="pone.0016038-Valente1">[1]</xref>, <xref ref-type="bibr" rid="pone.0016038-Bonifati1">[2]</xref>. PINK1 is a ubiquitously expressed serine/threonine kinase with a mitochondrial targeting sequence that directs import of PINK1 into mitochondria <xref ref-type="bibr" rid="pone.0016038-Bonifati1">[2]</xref>, <xref ref-type="bibr" rid="pone.0016038-Valente2">[3]</xref>, <xref ref-type="bibr" rid="pone.0016038-Silvestri1">[4]</xref>. In cultured cells, PINK1 protects against oxidative stress-induced cytochrome c release and apoptosis through phosphorylation of the mitochondrial chaperone TRAP1 <xref ref-type="bibr" rid="pone.0016038-Pridgeon1">[5]</xref>. <italic>Pink1</italic>-deficient <italic>Drosophila</italic> displayed mitochondrial degeneration associated with apoptotic muscle degeneration and DA neuron loss, which could be rescued by overexpression of Parkin <xref ref-type="bibr" rid="pone.0016038-Clark1">[6]</xref>, <xref ref-type="bibr" rid="pone.0016038-Park1">[7]</xref>, <xref ref-type="bibr" rid="pone.0016038-Yang1">[8]</xref>, <xref ref-type="bibr" rid="pone.0016038-Poole1">[9]</xref>. Work in cultured mammalian cells has shown that PINK1 directly phosphorylates Parkin <xref ref-type="bibr" rid="pone.0016038-Kim1">[10]</xref> and that PINK1 is required for recruitment of Parkin to mitochondria with impaired membrane potential <xref ref-type="bibr" rid="pone.0016038-Narendra1">[11]</xref>, <xref ref-type="bibr" rid="pone.0016038-VivesBauza1">[12]</xref>. In turn, Parkin promotes the degradation of functionally impaired mitochondria through ubiquitination-dependent autophagy <xref ref-type="bibr" rid="pone.0016038-Narendra1">[11]</xref>, <xref ref-type="bibr" rid="pone.0016038-VivesBauza1">[12]</xref>, <xref ref-type="bibr" rid="pone.0016038-Geisler1">[13]</xref>. Thus, PINK1 and Parkin cooperate in mitochondrial quality control by selectively promoting the degradation of dysfunctional mitochondria <xref ref-type="bibr" rid="pone.0016038-Bueler1">[14]</xref>, <xref ref-type="bibr" rid="pone.0016038-Dagda1">[15]</xref>. In contrast to the severe mitochondrial defects and degenerative phenotypes of <italic>Pink1</italic>-deficient flies, mice lacking <italic>Pink1</italic> showed normal numbers and morphology of mitochondria and failed to develop DA neuron loss <xref ref-type="bibr" rid="pone.0016038-Kitada1">[16]</xref>, <xref ref-type="bibr" rid="pone.0016038-Gispert1">[17]</xref>. Instead, they manifested milder defects, including impaired evoked DA release and mitochondrial respiration in the striatum <xref ref-type="bibr" rid="pone.0016038-Kitada1">[16]</xref>, <xref ref-type="bibr" rid="pone.0016038-Gispert1">[17]</xref>, <xref ref-type="bibr" rid="pone.0016038-Gautier1">[18]</xref>. The reason for the different phenotypes in mice and <italic>Drosophila</italic> is not clear, but it is conceivable that mice have a greater capacity to compensate for <italic>Pink1</italic> deficiency than flies. Such compensatory changes may include enhanced autophagy <xref ref-type="bibr" rid="pone.0016038-Dagda2">[19]</xref>, <xref ref-type="bibr" rid="pone.0016038-Cherra1">[20]</xref> or increased mitochondrial biogenesis <xref ref-type="bibr" rid="pone.0016038-WoodKaczmar1">[21]</xref>. Alternatively, <italic>Pink1</italic>-defcient mice may compensate through changes in the expression of genes that protect against the effects of <italic>Pink1</italic> ablation <italic>in vivo</italic>, possibly downstream of mitochondrial dysfunction. It has also not been studied whether <italic>Pink1</italic> deficiency affects the activity of cell death pathways implicated in PD, such as the MAP kinase pathway <xref ref-type="bibr" rid="pone.0016038-Burke1">[22]</xref>. To further study the consequences of <italic>Pink1</italic> gene deletion in mice and its effects on gene expression in the nigrostriatal system, we have generated and analyzed a new line of <italic>Pink1</italic>-deficient mice. Here we demonstrate that mitochondria from the brain of <italic>Pink1</italic>-deficient mice undergo Ca<sup>2+</sup>-induced permeability transition at a lower threshold and that pro-apoptotic Jun N-terminal kinase (JNK) signaling is increased in the substantia nigra of <italic>Pink1<sup>−/−</sup></italic> mice. Importantly, DA levels are reduced in <italic>Pink1<sup>−/−</sup></italic> mice six months and older, which is associated with increased DA turnover. We further show that ablation of <italic>Pink1</italic> results in reduced cytokine-induced NF-κB activity in <italic>Pink1<sup>−/−</sup></italic> embryonic fibroblasts and increased levels of IL-1β, IL-10 and IL-12 in the striatum of <italic>Pink1<sup>−/−</sup></italic> mice challenged with a low dose of LPS. Quantitative transcriptional profiling revealed that genes known to become activated after dopaminergic lesions were upregulated in the striatum of two month-old <italic>Pink1<sup>−/−</sup></italic> mice, indicative of early dopaminergic dysfunction. Interestingly, several genes that participate in axonal regeneration and/or inhibit innate immune responses were overexpressed, while certain pro-inflammatory and apoptotic genes associated with neurodegeneration showed lower expression in <italic>Pink1<sup>−/−</sup></italic> mice. This suggests that <italic>Pink1<sup>−/−</sup></italic> mice may mitigate neurodegeneration by adapting the expression of a set of genes towards increased neuroprotection. Taken together, our results show that <italic>Pink1</italic> ablation enhances the sensitivity to Ca<sup>2+</sup>-induced mitochondrial permeability transition, triggers pro-apoptotic JNK signaling and causes a decline in striatal DA levels associated with increased DA turnover. Transcriptional profiling data suggest that <italic>Pink1</italic> deletion may cause neuroinflammation and axonal damage, which are compensated for by specific changes in gene expression. While these changes may in part prevent neurodegeneration in <italic>Pink1<sup>−/−</sup></italic> mice, increased expression of cytokines in the striatum in response to peripheral inflammation may cause enhanced sensitivity to neuroinflammation, oxidative stress and brain injury. Further characterization of the role of these mechanisms in neuroprotection or neuronal loss will lead to better animal models for recessive Parkinsonism, as well as the identification of pathways that may be exploited as future targets for PD therapy.</p>
    </sec>
    <sec id="s2">
      <title>Results</title>
      <sec id="s2a">
        <title>Generation and molecular characterization of <italic>Pink1</italic>-deficient mice</title>
        <p>Homologous recombination in mouse ES cells transfected with the targeting vector (construction described in the Methods) led to the replacement of <italic>Pink1</italic> exons 4 and 5 with a phosphoglycerate kinase (PGK) promoter-driven neomycin phosphotransferase (neo) expression cassette and the deletion of essential portions of the PINK1 kinase domain (<xref ref-type="fig" rid="pone-0016038-g001">Figure 1</xref>). About 2% of the G418-resistant ES colonies harbored a heterozygous deletion of the <italic>Pink1</italic> gene (<xref ref-type="fig" rid="pone-0016038-g001">Fig. 1C</xref>). These gene-targeted clones were identified by PCR screening with primers P1 and P2 (<xref ref-type="fig" rid="pone-0016038-g001">Fig. 1</xref>) and subsequently confirmed by Southern blot analysis using probes homologous to sequences 5′ and 3′ of the targeting vector (<xref ref-type="fig" rid="pone-0016038-g002">Fig. 2A</xref>). Internal probes were used to rule out additional random insertions of the targeting vector in the genome of the targeted clones (data not shown). Injection of two gene-targeted ES cell clones yielded highly chimeric mice that transmitted the <italic>Pink1</italic> gene deletion to their offspring. Genomic Southern blot analysis of tail DNA from the F2 generation demonstrated the presence of all three genotypes (<xref ref-type="fig" rid="pone-0016038-g002">Fig. 2B</xref>). Next, we verified that <italic>Pink1<sup>−/−</sup></italic> mice lacked functional <italic>Pink1</italic> mRNA. First, expression of exon 4-containing <italic>PINK1</italic> transcripts was quantified by real-time reverse transcription PCR with primers located in <italic>Pink1</italic> exon 3 and exon 4, the latter of which is deleted in the mutant <italic>Pink1</italic> allele. <italic>Pink1</italic> mRNA expression was normalized to 18S rRNA levels in the same samples. The ratio of <italic>Pink1</italic> mRNA to 18S rRNA was 0.82±0.12 for wildtype mice (n = 3). A single <italic>Pink1<sup>+/−</sup></italic> mouse showed a value of 0.52 (63% of wildtype), while <italic>Pink1<sup>−/−</sup></italic> mice yielded an average signal of 0±0 (n = 6). This shows that no exon 4-containing <italic>Pink1</italic> transcripts were detected in <italic>Pink1<sup>−/−</sup></italic> mice. Second, to analyze for the possibility of alternatively spliced transcripts originating from the mutated <italic>Pink1</italic> allele, we carried out PCR with forward primers located in exon 3 and reverse primers located in exon 6, 7 or 8. These primer pairs are expected to generate PCR products of specific lengths for the <italic>Pink1</italic> wildtype allele, and correspondingly shorter PCR products if alternatively spliced mutant <italic>Pink1</italic> transcripts are present in cells (<xref ref-type="fig" rid="pone-0016038-g003">Fig. 3A</xref>). All expected bands for full-length <italic>Pink1</italic> transcripts were detected in wildtype and heterozygous mutant (<italic>Pink1<sup>+/−</sup></italic>) animals. In contrast, the <italic>Pink1<sup>−/−</sup></italic> mice failed to produce the same bands (as expected) as well as any bands indicative of alternative splicing (<xref ref-type="fig" rid="pone-0016038-g003">Fig. 3A</xref>). These results show that alternative splicing (exon 4/5 skipping) does not occur in <italic>Pink1<sup>−/−</sup></italic> mice. Third, we carried out real-time PCR with primers located in exon 1 and 3. As shown in <xref ref-type="fig" rid="pone-0016038-g003">Fig. 3B</xref>, the levels of transcripts encompassing exons 1–3 in the brain of <italic>Pink1<sup>−/−</sup></italic> mice were reduced to 6.8% of wildtype. Using an N-terminal antibody against PINK1 <xref ref-type="bibr" rid="pone.0016038-Weihofen1">[23]</xref>, we also examined whether a low amount (less than 6.8%) of a truncated form of PINK1 might still be expressed in <italic>Pink1<sup>−/−</sup></italic> mice. We used total brain, heart and embryonic fibroblast extracts from wildtype and <italic>Pink1<sup>−/−</sup></italic> mice for Western blot analysis. However, although the antibody was shown to detect PINK1 in transfected cells <xref ref-type="bibr" rid="pone.0016038-Weihofen1">[23]</xref>, it was not sensitive enough to reveal the much lower levels of endogenous PINK1, because no specific bands of either 66 kDa (mitochondrial PINK1) or 55 kDa (cytosolic PINK1) were observed in any of the wildtype tissues and cells tested (data not shown). The lack of suitable antibodies to detect endogenous Pink1 was also reported by others <xref ref-type="bibr" rid="pone.0016038-Gispert1">[17]</xref>. We conclude that the targeted <italic>Pink1</italic> gene deletion prevented the generation of normal and aberrantly spliced <italic>Pink1</italic> transcripts. Furthermore, if <italic>Pink1<sup>−/−</sup></italic> mice express an N-terminal portion of PINK1 protein, its levels are very low (less than 6.8% of normal amounts) and it lacks any kinase activity. Therefore, the mice described in this work are functionally PINK1-deficient.</p>
        <fig id="pone-0016038-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0016038.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Inactivation of the mouse <italic>Pink1</italic> locus by gene targeting in ES cells.</title>
            <p>(A) Mouse <italic>Pink1</italic> gene structure, (B) targeting vector and (C) mutated <italic>Pink1</italic> gene lacking exons 4 and 5 after homologous recombination with the targeting vector. The PINK1 kinase domain is encoded within exons 2–8, with exons 4 and 5 specifying amino acids 257–374. Active site Asp362 and at least 15 familial PD-associated <italic>Pink1</italic> mutations cluster in exons 4 and 5 <xref ref-type="bibr" rid="pone.0016038-Mills1">[143]</xref>.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0016038.g001" xlink:type="simple"/>
        </fig>
        <fig id="pone-0016038-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0016038.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Southern blot analysis of ES cell colonies and F2 generation mice.</title>
            <p>(A) Genomic DNA from PCR-positive ES cell clones was double-digested with NcoI/SacI or NdeI/XbaI and hybridized with the indicated probes. The location of the two probes and expected sizes of the various DNA fragments for wildtype (WT) and <italic>Pink1<sup>+/−</sup></italic> ES cells are shown in <xref ref-type="fig" rid="pone-0016038-g001">Figure 1</xref>. (B) Tail DNA from offspring of <italic>Pink1<sup>+/−</sup></italic> breeder pairs was digested with NcoI and SacI and analyzed by Southern blot using “outside exon 8” probe. The 4513 bp band indicates the wildtype <italic>Pink1</italic> allele and the 4152 bp band is diagnostic for the mutated <italic>Pink1</italic> allele. Location of the probe and restriction enzyme cleavage sites are shown in <xref ref-type="fig" rid="pone-0016038-g001">Figure 1</xref>.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0016038.g002" xlink:type="simple"/>
        </fig>
        <fig id="pone-0016038-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0016038.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Analysis and quantification of <italic>Pink1</italic> mRNA expression.</title>
            <p>Total RNA isolated from the brain of mice was converted to cDNA. (A) PCR with a forward primer located in exon 3 and reverse primers located in exon 6, 7 or 8, generating expected PCR products of 480, 624 and 1001 bp for the <italic>Pink1</italic> wildtype allele in wildtype and <italic>Pink1<sup>+/−</sup></italic> samples. In contrast, PCR products of 133, 149 and 289 that would arise if exon 3 were directly spliced to exon 6, 7, or 8 in transcripts derived from the mutant <italic>Pink1</italic> allele were absent in both <italic>Pink1<sup>+/−</sup></italic> and <italic>Pink1<sup>−/−</sup></italic> samples. This shows that alternatively spliced transcripts are <italic>not</italic> generated from the disrupted <italic>Pink1</italic> allele. (B) Quantitative real-time PCR with primers located in exon 1 (forward) and exon 3 (reverse) showing that <italic>Pink1<sup>−/−</sup></italic> mice express at most 6.8% of a truncated <italic>Pink1</italic> mRNA encompassing exons 1–3, compared to wildtype mice. However, such a truncated mRNA would not give rise to any PINK1 protein with kinase activity (see main text).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0016038.g003" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2b">
        <title>Brain mitochondria from <italic>Pink1</italic>-deficient mice display reduced threshold for calcium-induced permeability transition pore (PTP) opening</title>
        <p>Recently, it has been shown that mitochondria of <italic>Pink1</italic>-deficient neurons accumulate higher basal levels of Ca<sup>2+</sup> in the matrix (due to reduced calcium efflux capacity) and display reduced mitochondrial Ca<sup>2+</sup> storage capacity associated with Ca<sup>2+</sup> overload <xref ref-type="bibr" rid="pone.0016038-Gandhi1">[24]</xref>. To study whether mitochondria from the brain of <italic>Pink1</italic>-deficient mice show increased sensitivity to Ca<sup>2+</sup>, we exposed preparations of Ficoll-purified whole brain mitochondria from two month-old <italic>Pink1</italic>-deficient mice and wildtype controls to increasing concentrations of Ca<sup>2+</sup>, and measured PTP opening using the Ca<sup>2+</sup>-sensitive fluorescent dye CaG5N and TMRE to monitor changes in mitochondrial membrane potential (ΔΨ<sub>M</sub>) <xref ref-type="bibr" rid="pone.0016038-Brown1">[25]</xref>. <italic>Pink1</italic>-deficient brain mitochondria displayed a significant reduction in Ca<sup>2+</sup> buffering capacity, which could be ameliorated by the addition of the PTP inhibitor cyclosporine A (CsA) (<xref ref-type="fig" rid="pone-0016038-g004">Fig. 4A</xref>). As a consequence mitochondria from <italic>Pink1<sup>−/−</sup></italic> mice underwent permeability transition (mPT) at significantly lower concentrations of Ca <sup>2+</sup> compared to those of wildtype mice (<xref ref-type="fig" rid="pone-0016038-g004">Fig. 4B</xref>). Because CaG5N is an indicator of the <italic>extra</italic>-mitochondrial calcium concentration, the results cannot be attributed to differences in the dye loading capacity between wildtype and <italic>Pink1<sup>−/−</sup></italic> mitochondria. We also measured mitochondrial production of reactive oxygen species (ROS) <xref ref-type="bibr" rid="pone.0016038-Brown1">[25]</xref> but found no difference in ROS production between mitochondria purified from <italic>Pink1</italic>-deficient and wildtype brain (data not shown), consistent with previous results <xref ref-type="bibr" rid="pone.0016038-Gautier1">[18]</xref>.</p>
        <fig id="pone-0016038-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0016038.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title><italic>Pink1<sup>−/−</sup></italic> brain mitochondria have significantly lower Ca<sup>2+</sup> load capacity.</title>
            <p>Brain mitochondria were isolated from 2 month-old male wildtype (WT) and <italic>Pink1<sup>−/−</sup></italic> (PINK1-KO) mice to measure calcium load capacity. Mitochondrial protein (200 µg) from each genotype was incubated in a 2-ml reaction mixture containing 125 mM KCl buffer (37°C) along with fluorescence indicators: 100 nM Calcium Green 5-N (for measurement of extra-mitochondrial calcium concentration; excitation 506 nm, emission 532 nm) and 100 nM TMRE (for measurement of membrane potential; excitation 550 nm, emission 575 nm). Mitochondrial bioenergetic coupling was assessed by following changes in membrane potential (TMRE fluorescence, data not shown) following the addition of pyruvate + malate (PM), ADP (A) and oligomycin (O) at 1, 2 and 3 min respectively. Calcium infusion began at 5 min (rate of 160 nmol/mg protein/min) and changes in extra-mitochondrial Ca<sup>2+</sup> were assessed (CaG5N fluorescence). In Panel A, representative traces are shown to depict the calcium uptake and storage capacity before the opening of the mitochondrial permeability transition (mPT) pore. Mitochondria from PINK1-KO mice had decreased calcium load capacity, indicated by the earlier onset of mPT (sharp rise in extra-mitochondrial Ca<sup>2+</sup>) as compared to WT mice. Calcium load capacity in PINK-KO mice was increased by incubating mitochondria with cyclosporine A (CSA, 1 µM), a specific inhibitor of the PTP, showing that the reduced calcium load capacity was due to enhanced mPT. In Panel B, quantitative measurements of maximal calcium load capacity before mPT for mitochondria isolated from WT and PINK1-KO mice are shown and expressed as nmol Ca<sup>2+</sup> infused/mg protein. The graph in panel B illustrates a significant loss of calcium load capacity in PINK1-KO mice (*<italic>P</italic>&lt;0.05, n = 4 mice per genotype).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0016038.g004" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2c">
        <title>Accumulation of phosphorylated c-Jun in the substantia nigra of <italic>Pink1<sup>−/−</sup></italic> mice</title>
        <p>JNK is a member of the MAP kinase family and has been implicated in neuronal cell death in a variety of circumstances including PD pathogenesis <xref ref-type="bibr" rid="pone.0016038-Burke1">[22]</xref>. JNK is activated by oxidative and other types of stress and in turn phosphorylates c-Jun, its major substrate. In <italic>Drosophila</italic>, Parkin negatively regulates JNK activity <xref ref-type="bibr" rid="pone.0016038-Cha1">[26]</xref>. To assess JNK activity in the nigrostriatal system of mice, we stained wildtype and <italic>Pink1<sup>−/−</sup></italic> brain sections containing the substantia nigra with an antibody to phosphorylated c-Jun using the nickel-enhanced DAB method. Interestingly, we found that phospho-c-Jun accumulated in the substantia nigra of <italic>Pink1<sup>−/−</sup></italic> but not wildtype mice (<xref ref-type="fig" rid="pone-0016038-g005">Fig. 5</xref>). At least a proportion of the phospho-c-Jun signals are most likely within nuclei of dopaminergic neurons, as they are surrounded by cytosol positive for tyrosine hydroxylase (TH) (arrows in <xref ref-type="fig" rid="pone-0016038-g005">Fig. 5C–F</xref>). To verify that phospho-c-Jun was expressed in dopaminergic neurons we carried out double labeling of phospho-c-Jun and TH using fluorescent secondary antibodies for analysis by confocal microcopy. However, phospho-c-Jun was not detected by fluorescent immunohistochemistry, suggesting that its expression was very weak (see <xref ref-type="sec" rid="s3">Discussion</xref>). Nonetheless, expression of phosphorylated c-Jun was specific for <italic>Pink1</italic>-deficient mice, as all three <italic>Pink1</italic> knockout mice showed phospho-c-Jun expression while none of the wildtype mice did. These results show that increased JNK activation occurs in the substantia nigra of <italic>Pink1</italic>-deficient mice and may play a role in <italic>Pink1</italic>-related Parkinsonism.</p>
        <fig id="pone-0016038-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0016038.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>Accumulation of phospho-c-Jun in the substantia nigra of <italic>Pink1<sup>−/−</sup></italic> mice.</title>
            <p>Cryosections of the substantia nigra from wildtype (A–B) and <italic>Pink1<sup>−/−</sup></italic> mice (C–F) were stained with antibodies against phospho-c-Jun (nickel-DAB staining) and subsequently TH (fluorescent) as described in the Methods. Arrows in panels C–F point to cells expressing nuclear phospho-c-Jun that is surrounded by TH-positive cytosol, suggesting that these cells are dopaminergic neurons. AP coordinates of sections according to the mouse stereotaxic atlas (Franklin and Paxinos, The Mouse Brain in Stereotaxic Coordinates, Third Edition 2007) are indicated to demonstrate that phospho-c-Jun was expressed in distantly spaced sections of <italic>Pink1<sup>−/−</sup></italic> mice (C–F), including sections anatomically matched to wildtype control mice (compare A–B and C–D). All three <italic>Pink1<sup>−/−</sup></italic> mice but none of the wildtype mice showed expression of phospho-c-Jun in a subpopulation of TH-positive neurons.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0016038.g005" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2d">
        <title>Decreased dopamine levels associated with increased dopamine turnover in <italic>Pink1<sup>−/−</sup></italic> mice aged six months and older</title>
        <p>To study whether the targeted <italic>Pink1</italic> mutation affected dopaminergic parameters, we measured the levels of DA in the striatum by HPLC in mice between 2 and 12 months of age. <italic>Pink1<sup>−/−</sup></italic> mice aged 6 months and older had significantly lower DA levels in the striatum than their wildtype controls (<xref ref-type="fig" rid="pone-0016038-g006">Fig. 6A</xref>). However, stereological quantification of DA neuron numbers in 1-year old <italic>Pink1<sup>−/−</sup></italic> and wildtype mice showed no significant difference, although the average number was 22% lower in <italic>Pink1<sup>−/−</sup></italic> mice (<xref ref-type="fig" rid="pone-0016038-g006">Fig. 6B</xref>). This suggested that dopaminergic neurons of <italic>Pink1<sup>−/−</sup></italic> mice synthesize less dopamine and/or that dopamine metabolism is increased. In support of this, we show, for the first time, that DA turnover is increased in <italic>Pink1<sup>−/−</sup></italic> mice at those ages where DA levels are lower (<xref ref-type="fig" rid="pone-0016038-g006">Fig. 6C</xref>). These results confirm that <italic>Pink1</italic> deficiency can cause lower DA levels <xref ref-type="bibr" rid="pone.0016038-Gispert1">[17]</xref> and further suggest that increased DA turnover may be involved in this defect.</p>
        <fig id="pone-0016038-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0016038.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>Dopamine levels, dopamine turnover and dopamine neuron counts.</title>
            <p>(A) Decreased DA levels in the striatum of <italic>Pink1<sup>−/−</sup></italic> mice aged 6 months and older. (B) Normal counts of dopaminergic neurons in the substantia nigra pars compacta (SNc) of 1-year old <italic>Pink1<sup>−/−</sup></italic> mice. (C) Increased DA turnover in <italic>Pink1<sup>−/−</sup></italic> mice. Eight mice per genotype were used for catecholamine analysis (A and C). Five wildtype and six <italic>Pink1<sup>−/−</sup></italic> mice were used to determine nigral DA neuron numbers by unbiased stereology (B). * <italic>P</italic>&lt;0.05, ** <italic>P</italic>&lt;0.01, *** <italic>P</italic>&lt;0.001.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0016038.g006" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2e">
        <title>Loss of <italic>Pink1</italic> activates expression of stress-inducible transcription factor genes</title>
        <p>To gain additional insights into mechanisms promoting dopaminergic dysfunction in response to <italic>Pink1</italic> ablation, we compared striatal gene expression profiles between two month-old wildtype and <italic>Pink1<sup>−/−</sup></italic> mice. We focused on cAMP/Ca<sup>2+</sup>-regulated genes and genes of the Akt/protein kinase B (Akt/PKB) and nuclear factor kappa-β (NF-κB) pathways, because abnormalities in these pathways have been implicated in PD <xref ref-type="bibr" rid="pone.0016038-Yang2">[27]</xref>, <xref ref-type="bibr" rid="pone.0016038-Timmons1">[28]</xref>, <xref ref-type="bibr" rid="pone.0016038-Mogi1">[29]</xref>. We found that several of the upregulated genes encoded stress-inducible transcription factors of the ATF and AP1 families, including activating transcription factor 3 (ATF-3), c-fos, FosB, JunB and Egr-2 (<xref ref-type="table" rid="pone-0016038-t001">Table 1</xref>). ATF3 is induced by multiple signals, including inflammatory cytokines, DNA-damaging agents and physiological stresses <xref ref-type="bibr" rid="pone.0016038-Chen1">[30]</xref>, <xref ref-type="bibr" rid="pone.0016038-Lu1">[31]</xref>. Interestingly, increased striatal expression of Fos-related antigens and JunB has been observed following neuronal injury and degeneration in the DA system <xref ref-type="bibr" rid="pone.0016038-Dragunow1">[32]</xref>, <xref ref-type="bibr" rid="pone.0016038-Joh1">[33]</xref>. Moreover, striatal c-fos expression is regulated by DA <xref ref-type="bibr" rid="pone.0016038-Badiani1">[34]</xref> and, in the DA-depleted striatum, may be induced via compensatory super-sensitivity of DA receptors <xref ref-type="bibr" rid="pone.0016038-Svenningsson1">[35]</xref>, <xref ref-type="bibr" rid="pone.0016038-Robertson1">[36]</xref>. Likewise, expression of Egr-2 is regulated in a D1 and D2 DA receptor-dependent fashion <xref ref-type="bibr" rid="pone.0016038-Beauvais1">[37]</xref>, <xref ref-type="bibr" rid="pone.0016038-DeSteno1">[38]</xref>.</p>
        <table-wrap id="pone-0016038-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0016038.t001</object-id><label>Table 1</label><caption>
            <title>Genes with significantly altered expression in the striatum of <italic>Pink1<sup>−/−</sup></italic> mice.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pone-0016038-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0016038.t001" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Gene</td>
                <td align="left" colspan="1" rowspan="1">Description</td>
                <td align="left" colspan="2" rowspan="1">Threshold Cycles</td>
                <td align="left" colspan="2" rowspan="1">Expression relative to HKG</td>
                <td align="left" colspan="1" rowspan="1">Expression</td>
                <td align="left" colspan="1" rowspan="1">
                  <italic>P</italic>
                </td>
                <td align="left" colspan="1" rowspan="1">N</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Ct <italic>WT</italic></td>
                <td align="left" colspan="1" rowspan="1">Ct <italic>Pink1<sup>−/−</sup></italic></td>
                <td align="left" colspan="1" rowspan="1">2<sup>−(AVG ΔCt)</sup><italic>WT</italic></td>
                <td align="left" colspan="1" rowspan="1">2<sup>−(AVG ΔCt)</sup><italic>Pink1<sup>−/−</sup></italic></td>
                <td align="left" colspan="1" rowspan="1">
                  <italic>Pink1<sup>−/−</sup>/WT</italic>
                </td>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="9" rowspan="1">
                  <bold>
                    <italic>Upregulated Genes</italic>
                  </bold>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Fos</td>
                <td align="left" colspan="1" rowspan="1">FBJ osteosarcoma oncogene</td>
                <td align="left" colspan="1" rowspan="1">29.29±1.40</td>
                <td align="left" colspan="1" rowspan="1">27.36±1.62</td>
                <td align="left" colspan="1" rowspan="1">1.81×10<sup>−2</sup></td>
                <td align="left" colspan="1" rowspan="1">5.06×10<sup>−2</sup></td>
                <td align="left" colspan="1" rowspan="1">2.80</td>
                <td align="left" colspan="1" rowspan="1">0.031</td>
                <td align="left" colspan="1" rowspan="1">5</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Tnfrsf10b</td>
                <td align="left" colspan="1" rowspan="1">TRAIL receptor 2</td>
                <td align="left" colspan="1" rowspan="1">34.41±0.56</td>
                <td align="left" colspan="1" rowspan="1">33.5±0.25</td>
                <td align="left" colspan="1" rowspan="1">3.74×10<sup>−4</sup></td>
                <td align="left" colspan="1" rowspan="1">6.46×10<sup>−4</sup></td>
                <td align="left" colspan="1" rowspan="1">1.72</td>
                <td align="left" colspan="1" rowspan="1">0.048</td>
                <td align="left" colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Nfkbia</td>
                <td align="left" colspan="1" rowspan="1">NF-κB inhibitor-α</td>
                <td align="left" colspan="1" rowspan="1">27.71±0.54</td>
                <td align="left" colspan="1" rowspan="1">26.76±0.30</td>
                <td align="left" colspan="1" rowspan="1">4.35×10<sup>−2</sup></td>
                <td align="left" colspan="1" rowspan="1">6.60×10<sup>−2</sup></td>
                <td align="left" colspan="1" rowspan="1">1.52</td>
                <td align="left" colspan="1" rowspan="1">0.0002</td>
                <td align="left" colspan="1" rowspan="1">5</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Fosb</td>
                <td align="left" colspan="1" rowspan="1">FBJ osteosarcoma oncogene B</td>
                <td align="left" colspan="1" rowspan="1">30.73±1.31</td>
                <td align="left" colspan="1" rowspan="1">28.62±0.97</td>
                <td align="left" colspan="1" rowspan="1">2.65×10<sup>−3</sup></td>
                <td align="left" colspan="1" rowspan="1">8.24×10<sup>−3</sup></td>
                <td align="left" colspan="1" rowspan="1">3.12</td>
                <td align="left" colspan="1" rowspan="1">0.019</td>
                <td align="left" colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Cyr61</td>
                <td align="left" colspan="1" rowspan="1">Cysteine-rich protein 61</td>
                <td align="left" colspan="1" rowspan="1">30.15±0.40</td>
                <td align="left" colspan="1" rowspan="1">28.17±1.10</td>
                <td align="left" colspan="1" rowspan="1">3.97×10<sup>−3</sup></td>
                <td align="left" colspan="1" rowspan="1">1.12×10<sup>−2</sup></td>
                <td align="left" colspan="1" rowspan="1">2.83</td>
                <td align="left" colspan="1" rowspan="1">0.018</td>
                <td align="left" colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">JunB</td>
                <td align="left" colspan="1" rowspan="1">JunB oncogene</td>
                <td align="left" colspan="1" rowspan="1">32.46±1.23</td>
                <td align="left" colspan="1" rowspan="1">30.5±0.56</td>
                <td align="left" colspan="1" rowspan="1">7.99×10<sup>−4</sup></td>
                <td align="left" colspan="1" rowspan="1">2.24×10<sup>−3</sup></td>
                <td align="left" colspan="1" rowspan="1">2.80</td>
                <td align="left" colspan="1" rowspan="1">0.005</td>
                <td align="left" colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Egr2</td>
                <td align="left" colspan="1" rowspan="1">Early growth response 2</td>
                <td align="left" colspan="1" rowspan="1">28.51±1.17</td>
                <td align="left" colspan="1" rowspan="1">26.6±1.06</td>
                <td align="left" colspan="1" rowspan="1">1.24×10<sup>−2</sup></td>
                <td align="left" colspan="1" rowspan="1">3.34×10<sup>−2</sup></td>
                <td align="left" colspan="1" rowspan="1">2.68</td>
                <td align="left" colspan="1" rowspan="1">0.049</td>
                <td align="left" colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Atf3</td>
                <td align="left" colspan="1" rowspan="1">Activating transcription factor3</td>
                <td align="left" colspan="1" rowspan="1">33.2±0.30</td>
                <td align="left" colspan="1" rowspan="1">31.69±0.91</td>
                <td align="left" colspan="1" rowspan="1">4.78×10<sup>−4</sup></td>
                <td align="left" colspan="1" rowspan="1">9.82×10<sup>−4</sup></td>
                <td align="left" colspan="1" rowspan="1">2.05</td>
                <td align="left" colspan="1" rowspan="1">0.027</td>
                <td align="left" colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Dusp1</td>
                <td align="left" colspan="1" rowspan="1">Map kinase phosphatase-1</td>
                <td align="left" colspan="1" rowspan="1">26.6±0.28</td>
                <td align="left" colspan="1" rowspan="1">25.12±0.61</td>
                <td align="left" colspan="1" rowspan="1">4.64×10<sup>−2</sup></td>
                <td align="left" colspan="1" rowspan="1">9.34×10<sup>−2</sup></td>
                <td align="left" colspan="1" rowspan="1">2.01</td>
                <td align="left" colspan="1" rowspan="1">0.0005</td>
                <td align="left" colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Areg</td>
                <td align="left" colspan="1" rowspan="1">Amphiregulin</td>
                <td align="left" colspan="1" rowspan="1">34.1±0.62</td>
                <td align="left" colspan="1" rowspan="1">32.76±0.75</td>
                <td align="left" colspan="1" rowspan="1">2.56×10<sup>−4</sup></td>
                <td align="left" colspan="1" rowspan="1">4.68×10<sup>−4</sup></td>
                <td align="left" colspan="1" rowspan="1">1.83</td>
                <td align="left" colspan="1" rowspan="1">0.027</td>
                <td align="left" colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td align="left" colspan="9" rowspan="1">
                  <bold>
                    <italic>Down-regulated Genes</italic>
                  </bold>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Tnfrsf1b</td>
                <td align="left" colspan="1" rowspan="1">TNF receptor 2</td>
                <td align="left" colspan="1" rowspan="1">31.41±0.47</td>
                <td align="left" colspan="1" rowspan="1">32.21±0.73</td>
                <td align="left" colspan="1" rowspan="1">3.0×10<sup>−3</sup></td>
                <td align="left" colspan="1" rowspan="1">1.58×10<sup>−3</sup></td>
                <td align="left" colspan="1" rowspan="1">0.53</td>
                <td align="left" colspan="1" rowspan="1">0.01</td>
                <td align="left" colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Tnfrsf1a</td>
                <td align="left" colspan="1" rowspan="1">TNF receptor 1</td>
                <td align="left" colspan="1" rowspan="1">32.01±0.56</td>
                <td align="left" colspan="1" rowspan="1">32.49±0.63</td>
                <td align="left" colspan="1" rowspan="1">1.97×10<sup>−3</sup></td>
                <td align="left" colspan="1" rowspan="1">1.30×10<sup>−3</sup></td>
                <td align="left" colspan="1" rowspan="1">0.65</td>
                <td align="left" colspan="1" rowspan="1">0.022</td>
                <td align="left" colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Pcaf</td>
                <td align="left" colspan="1" rowspan="1">p300/CBP-associated factor</td>
                <td align="left" colspan="1" rowspan="1">26.56±0.52</td>
                <td align="left" colspan="1" rowspan="1">27.01±0.37</td>
                <td align="left" colspan="1" rowspan="1">8.72×10<sup>−2</sup></td>
                <td align="left" colspan="1" rowspan="1">5.76×10<sup>−2</sup></td>
                <td align="left" colspan="1" rowspan="1">0.65</td>
                <td align="left" colspan="1" rowspan="1">0.035</td>
                <td align="left" colspan="1" rowspan="1">4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Gsk3b</td>
                <td align="left" colspan="1" rowspan="1">Glycogen synthase kinase-3β</td>
                <td align="left" colspan="1" rowspan="1">25.38±0.71</td>
                <td align="left" colspan="1" rowspan="1">25.67±0.76</td>
                <td align="left" colspan="1" rowspan="1">2.55×10<sup>−1</sup></td>
                <td align="left" colspan="1" rowspan="1">1.70×10<sup>−1</sup></td>
                <td align="left" colspan="1" rowspan="1">0.66</td>
                <td align="left" colspan="1" rowspan="1">0.01</td>
                <td align="left" colspan="1" rowspan="1">4</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt101">
              <label/>
              <p>Gene expression was analyzed using NF-κB, PI3 kinase/Akt and cAMP/Ca<sup>2+</sup> signaling PCR Arrays (SA Biosciences) as described in the Methods. Ct values (mean ± SD) for individual genes are indicated for wildtype <italic>(WT)</italic> and <italic>Pink1<sup>−/−</sup></italic> mice. In addition, expression of each gene relative to the housekeeping genes (HKG) is indicated for WT and <italic>Pink1<sup>−/−</sup></italic> mice and was used to calculate the fold change in gene expression <italic>(Pink1<sup>−/−</sup>/WT).</italic> All PCR arrays contain five HKG (β-glucuronidase, hypoxanthine guanine phosphoribosyl transferase, heat shock protein 90-alpha, glyceraldehyde-3-phosphate dehydrogenase, and β-actin), to which the expression of the genes of interests is normalized. None of the HKG was differentially expressed between <italic>WT</italic> and <italic>Pink1<sup>−/−</sup></italic> mice. Data were evaluated and calculated with the ΔΔCt method using the RT<sup>2</sup> Profiler PCR Array Data Analysis software and resources available online (<ext-link ext-link-type="uri" xlink:href="http://sabiosciences.com/pcr/arrayanalysis.php" xlink:type="simple">http://sabiosciences.com/pcr/arrayanalysis.php</ext-link>). The p values were calculated based on a Student's t-test of the replicate 2<sup>−(AVG ΔCt)</sup> values for each gene in the <italic>WT</italic> and <italic>Pink1<sup>−/−</sup></italic> groups. All genes with a p&lt;0.05 that were upregulated or down-regulated by at least a factor of 1.5 are shown. N is the number of data points available for a given gene for <italic>both</italic> genotypes after running five arrays (five mice per genotype were analyzed). Occasionally, a well (gene) yielded no signal at all for reasons that are unrelated to actual lack of expression. For example, if a specific gene became detectable at PCR cycle number 25 in four mice but showed no expression in the fifth mouse of the same genotype, we concluded that this must be an experimental/technical error rather than actual lack of expression and omitted the corresponding data. However, we still used five data points for the other genotype if available. For a description of the function of the listed genes in innate immunity, MAPK signaling and/or their involvement and regulation in PD and models of PD, see the main text and references therein.</p>
            </fn>
          </table-wrap-foot></table-wrap>
      </sec>
      <sec id="s2f">
        <title>Ablation of <italic>PINK1</italic> increases expression of Cyr61 and Amphiregulin</title>
        <p>We also found significantly increased expression of Cyr61 and Amphiregulin in the striatum of <italic>Pink1</italic>-deficient mice (<xref ref-type="table" rid="pone-0016038-t001">Table 1</xref>). Cyr61 is an immediate early gene induced downstream of JNK activation that has been linked to neurodegeneration <xref ref-type="bibr" rid="pone.0016038-Kim2">[39]</xref>. Cyr61 transcription is negatively regulated by the forkhead transcription factor FOXO3a <xref ref-type="bibr" rid="pone.0016038-Lee1">[40]</xref>, which has been shown to activate the <italic>Pink1</italic> gene under conditions of growth factor deprivation <xref ref-type="bibr" rid="pone.0016038-Mei1">[41]</xref>. Amphiregulin is a mitogen for adult neural stem cells <xref ref-type="bibr" rid="pone.0016038-Falk1">[42]</xref> and acts as an autocrine survival factor for sensory neurons where it promotes axonal outgrowth <xref ref-type="bibr" rid="pone.0016038-Nilsson1">[43]</xref>.</p>
      </sec>
      <sec id="s2g">
        <title>Altered expression of genes that regulate innate immunity and MAP kinase signaling in the striatum of <italic>Pink1</italic>-deficient mice</title>
        <p><italic>Pink1<sup>−/−</sup></italic> mice displayed altered expression of many genes that regulate innate immune responses and the MAPK pathway (<xref ref-type="table" rid="pone-0016038-t001">Table 1</xref>). For example, the inhibitor-α of NF-κB (IκB-α), MAPK phosphatase-1 (MKP-1/Dusp-1) and the receptor for tumor necrosis factor-related apoptosis inducing ligand (TRAIL-R2) were all upregulated in <italic>Pink1<sup>−/−</sup></italic> striatum. IkB-α provides a negative feedback regulation for NF-κB signaling <xref ref-type="bibr" rid="pone.0016038-Sun1">[44]</xref>, <xref ref-type="bibr" rid="pone.0016038-Zhou1">[45]</xref>. MKP-1 inactivates p38 MAPK and JNK through dephosphorylation and via NF-κB regulation <xref ref-type="bibr" rid="pone.0016038-Wang1">[46]</xref> and functions as an important negative regulator of innate and adaptive immune responses <xref ref-type="bibr" rid="pone.0016038-Wang1">[46]</xref>, <xref ref-type="bibr" rid="pone.0016038-Lang1">[47]</xref>, <xref ref-type="bibr" rid="pone.0016038-Liu1">[48]</xref>. TRAIL-R2 is induced by a variety of stress factors and its activation involves both NF-κB and p53 dependent pathways <xref ref-type="bibr" rid="pone.0016038-Chen2">[49]</xref>, <xref ref-type="bibr" rid="pone.0016038-Tang1">[50]</xref>. Four genes were expressed at lower levels in the striatum of <italic>Pink1<sup>−/−</sup></italic> mice (<xref ref-type="table" rid="pone-0016038-t001">Table 1</xref>). These were p300/CREB-binding protein associated factor (p300/CBP-associated factor, PCAF), tumor necrosis factor receptor-1α (TNF-R1), tumor necrosis factor receptor-1β (TNF-R2), and glycogen synthase kinase-3 beta (GSK-3β). The histone acetyltransferase PCAF functions as a transcriptional co-activator of a subset of NF-κB regulated genes <xref ref-type="bibr" rid="pone.0016038-Gerritsen1">[51]</xref>, including cyclooxygenase-2 (COX-2) <xref ref-type="bibr" rid="pone.0016038-Deng1">[52]</xref>. However, PCAF is also required for post-activation shut-off of NF-κB gene transcription through acetylation of p65 <xref ref-type="bibr" rid="pone.0016038-Kiernan1">[53]</xref>. TNF receptors mediate numerous functions in cells that range from inflammation, apoptosis and cell survival <xref ref-type="bibr" rid="pone.0016038-Wilson1">[54]</xref>, <xref ref-type="bibr" rid="pone.0016038-Silke1">[55]</xref>, <xref ref-type="bibr" rid="pone.0016038-Karin1">[56]</xref>. TNF-R engagement activates NF-κB signaling and the MAPK pathway and thus often results in tissue inflammation <xref ref-type="bibr" rid="pone.0016038-Karin1">[56]</xref>. GSK-3β has been linked to neurodegeneration and the neuropathology of PD <xref ref-type="bibr" rid="pone.0016038-Nagao1">[57]</xref>, <xref ref-type="bibr" rid="pone.0016038-GarciaGorostiaga1">[58]</xref>, <xref ref-type="bibr" rid="pone.0016038-Avraham1">[59]</xref>, <xref ref-type="bibr" rid="pone.0016038-Chen3">[60]</xref>. Taken together, these results show that several key regulators and effectors of the TNF-R, NF-κB and MAPK signaling pathways are abnormally expressed in the striatum of <italic>Pink1</italic>-deficient mice.</p>
      </sec>
      <sec id="s2h">
        <title>Basal and inflammatory cytokine-induced NF-κB activity is reduced in <italic>PINK1</italic>-deficient mouse embryonic fibroblasts (MEF)</title>
        <p>The transcriptional profiling results indicated abnormalities in TNF-R and NF-κB signaling in the striatum of <italic>Pink1</italic>-deficient mice. The inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin 1β (IL-1β) are potent inducers of NF-κB signaling <xref ref-type="bibr" rid="pone.0016038-Vallabhapurapu1">[61]</xref>, <xref ref-type="bibr" rid="pone.0016038-Verstrepen1">[62]</xref>. In addition bacterial LPS activates the NF-κB pathway via Toll-like receptor 4 (TLR-4) and TNF-α expression. To study basal and inflammatory cytokine-induced NF-κB activity, we transfected primary MEF from <italic>Pink1</italic>-deficient and wildtype mice with an NF-κB-luciferase reporter plasmid and measured luciferase activity before and after treatment of cells with TNF-α and IL-1β. Compared to wildtype MEF, fibroblasts derived from <italic>Pink1<sup>−/−</sup></italic> mice showed significantly reduced NF-κB activity in both the basal state and after treatment with inflammatory cytokines (<xref ref-type="fig" rid="pone-0016038-g007">Fig. 7A</xref>). Likewise, LPS-induced NF-κB activity was decreased in <italic>Pink1<sup>−/−</sup></italic> MEF (<xref ref-type="fig" rid="pone-0016038-g007">Fig. 7A</xref>). EGFP expression in control wells of wildtype and <italic>Pink1<sup>−/−</sup></italic> MEF (<xref ref-type="fig" rid="pone-0016038-g007">Fig. 7B</xref>) was used to confirm comparable transfection efficiency. These results show that lack of <italic>Pink1</italic> impairs NF-κB activity and reduces inflammatory signal-dependent NF-κB pathway induction.</p>
        <fig id="pone-0016038-g007" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0016038.g007</object-id>
          <label>Figure 7</label>
          <caption>
            <title>Basal and inflammatory signal-induced NF-κB activity is reduced in <italic>Pink1<sup>−/−</sup></italic> embryonic fibroblasts.</title>
            <p>Wildtype and <italic>Pink1<sup>−/−</sup></italic> MEF were transfected with plasmid pNF-κB-luc (Clontech). Twenty-four hours after transfection the cells were incubated for 8 hours with 30 ng/ml TNF-α, 10 ng/ml IL-1β, 100 ng/ml LPS or remained untreated (control) and luciferase activity was measured as described in the Methods. (A) NF-κB-dependent luciferase activity, expressed as relative light units (RLU) per mg protein. Data represent pooled values from two independent experiments with similar results. In each experiment luciferase activity was measured in five wells per condition. Non-transfected cells (NT) showed no luciferase activity. (B) Wildtype and <italic>Pink1<sup>−/−</sup></italic> fibroblasts were transfected with the same plasmid/lipofectamine mixture to ensure equal transfection efficiency, which was confirmed to be the case with an EGFP expression plasmid as described in the Methods. ** <italic>P</italic>&lt;0.01.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0016038.g007" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2i">
        <title><italic>Pink1<sup>−/−</sup></italic> mice show increased striatal levels of IL-1β, IL-12 and IL-10 after treatment with LPS</title>
        <p>Given the increased expression of anti-inflammatory genes in the striatum and enhanced JNK activity in the substantia nigra of <italic>Pink1<sup>−/−</sup></italic> mice, we were interested to test whether <italic>Pink1<sup>−/−</sup></italic> mice showed abnormal expression of inflammatory and/or anti-inflammatory cytokines in the striatum. The relative striatal levels of twelve cytokines (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IL-17α, TNF-α, G-CSF, GM-CSF) were measured using an enzyme-linked immunosorbent assay (ELISA). We did not find a significant difference in the expression of these cytokines between wildtype and <italic>Pink1<sup>−/−</sup></italic> mice (data not shown). However, after peripheral challenge with a low dose of LPS, <italic>Pink1<sup>−/−</sup></italic> mice expressed higher levels of IL-1β, IL-12 and IL-10 in the striatum compared to wildtype mice (<xref ref-type="fig" rid="pone-0016038-g008">Fig. 8A</xref>). In addition, a tendency for increased expression of IL-2 (p = 0.053), IL-4 (p = 0.085) and TNF-α (p = 0.072) was observed. In the brain, microglia cells are the major source for LPS-induced cytokine production <xref ref-type="bibr" rid="pone.0016038-Rivest1">[63]</xref>. Therefore we studied cytokine production of cultured neonatal microglia in response to LPS. The levels of IL-10 were significantly higher after LPS in <italic>Pink1<sup>−/−</sup></italic> but not wildtype microglia, suggesting that IL-10 secretion is potentiated in <italic>Pink1<sup>−/−</sup></italic> microglia (<xref ref-type="fig" rid="pone-0016038-g008">Fig. 8B</xref>). This is in agreement with increased IL-10 levels in the striatum of <italic>Pink1<sup>−/−</sup></italic> mice (<xref ref-type="fig" rid="pone-0016038-g008">Fig. 8A</xref>). However, IL-1β levels did not significantly increase in cultured microglia from either genotype (<xref ref-type="fig" rid="pone-0016038-g008">Fig. 8B</xref>) and IL-12 levels were too low to be detected with the ELISA (data not shown). In contrast, the expression of IL-6, TNF-α and G-CSF was dramatically induced after LPS in both genotypes, showing that the microglia cells were competent to respond to an inflammatory stimulus (<xref ref-type="fig" rid="pone-0016038-g008">Fig. 8C</xref>). As T cells can also synthesize cytokines, we quantified the expression of the T cell marker CD3 in the striatum by real-time PCR. T cells are not normally present in significant numbers in the brain. Consistent with this the expression of CD3 in the striatum of normal mice was very low, as evidenced by Ct values in the range of 39 (<xref ref-type="fig" rid="pone-0016038-g008">Fig. 8D</xref>). In addition, CD3 expression did not increase after LPS treatment. Thus, we believe that T cells are likely not involved in augmenting brain cytokine levels in LPS-treated <italic>Pink1<sup>−/−</sup></italic> mice. This is consistent with a role for T cells in antigen-specific adaptive immune responses, which take longer to develop than eight hours between LPS injection and cytokine analysis in our experiment. Taken together, these results show that <italic>Pink1<sup>−/−</sup></italic> mice display abnormal brain cytokine expression in response to peripheral LPS injection and suggest that <italic>Pink1<sup>−/−</sup></italic> mice may be more susceptible to inflammation-induced DA neuron death <xref ref-type="bibr" rid="pone.0016038-Gayle1">[64]</xref>, <xref ref-type="bibr" rid="pone.0016038-Ferrari1">[65]</xref>, <xref ref-type="bibr" rid="pone.0016038-PottGodoy1">[66]</xref>, <xref ref-type="bibr" rid="pone.0016038-Sriram1">[67]</xref>, <xref ref-type="bibr" rid="pone.0016038-McCoy1">[68]</xref>.</p>
        <fig id="pone-0016038-g008" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0016038.g008</object-id>
          <label>Figure 8</label>
          <caption>
            <title>Cytokine expression in the striatum and isolated microglial cultures.</title>
            <p>(A) Wildtype and <italic>Pink1<sup>−/−</sup></italic> mice (n = 4 mice/genotype) were injected ip with 0.33 µg LPS/g body weight. Cytokines in striatal homogenates (corresponding to 100 µg total protein) were measured eight hours later by ELISA as described in the <xref ref-type="sec" rid="s4">Materials and Methods</xref>. * <italic>P</italic>&lt;0.05, compared to wildtype mice. Basal cytokine levels, measured in a separate experiment, were not statistically different between wildtype and <italic>Pink1<sup>−/−</sup></italic> mice. (B) Microglial cultures derived from the forebrain of neonatal wildtype and <italic>Pink1<sup>−/−</sup></italic> mice were incubated with 100 ng/ml LPS for 24 hours in 24-well plates and the cytokines were measured with an ELISA as described in the Methods (n = 8 wells per condition). (C) Strong induction of IL-6, TNF-α and G-CSF in wildtype and <italic>Pink1<sup>−/−</sup></italic> microglia cells demonstrates that the cells were capable of responding to the LPS stimulus. In panels B and C, background-corrected absorbance is plotted (OD450 minus OD570). (D) Real-time PCR expression analysis of CD3 mRNA (specific T cell marker) in the striatum of control and LPS-treated wildtype and <italic>Pink1<sup>−/−</sup></italic> mice, showing that the T cell marker is barely detectable (Ct values of 39.67 and 38.46) and not increased by LPS treatment.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0016038.g008" xlink:type="simple"/>
        </fig>
      </sec>
    </sec>
    <sec id="s3">
      <title>Discussion</title>
      <sec id="s3a">
        <title>Ca<sup>2+</sup>-induced mitochondrial permeability transition is increased in the absence of <italic>Pink1</italic></title>
        <p>It has been shown that striatal mitochondria from <italic>Pink1<sup>−/−</sup></italic> mice show impaired state 3 respiratory activities of complex I and II and that <italic>Pink1<sup>−/−</sup></italic> cortical mitochondria are more sensitive to H<sub>2</sub>O<sub>2</sub>-induced defects, while the levels of anti-oxidant enzymes were normal <xref ref-type="bibr" rid="pone.0016038-Gautier1">[18]</xref>. Here, we show for the first time that isolated purified mitochondria from the brain of <italic>Pink1<sup>−/−</sup></italic> mice display an enhanced vulnerability to Ca<sup>2+</sup>-induced mPT. Whereas cultured neurons of <italic>Pink1<sup>−/−</sup></italic> mice were reported to be more sensitive to Ca<sup>2+</sup>-induced cell death due to Ca<sup>2+</sup> overload <xref ref-type="bibr" rid="pone.0016038-Gandhi1">[24]</xref>, mitochondria of <italic>Pink1</italic>-deficient mice did not appear to be more sensitive to Ca<sup>2+</sup> than mitochondria from wildtype mice <xref ref-type="bibr" rid="pone.0016038-Gautier1">[18]</xref>. This led to the conclusion that, independent of Ca<sup>2+</sup> and the mitochondrial PTP, <italic>Pink1<sup>−/−</sup></italic> mitochondria are more sensitive to stress <xref ref-type="bibr" rid="pone.0016038-Gautier1">[18]</xref>. However, in these experiments the swelling assay was used and only one concentration of Ca<sup>2+</sup> was tested. Additionally, a differential effect of Ca<sup>2+</sup> loading could have been missed due to low coupling of the mitochondrial preparations used in these experiments (RCR&lt;5). In contrast, we incubated highly coupled mitochondria (RCR&gt;10) with increasing concentrations of Ca<sup>2+</sup>, and measured mitochondrial Ca<sup>2+</sup> uptake and the sudden Ca<sup>2+</sup> release and loss of ΔΨ<sub>M</sub> at the time of PTP opening using the Ca<sup>2+</sup>-sensitive dye CaG5N and TMRE to monitor ΔΨ<sub>M</sub> <xref ref-type="bibr" rid="pone.0016038-Brown1">[25]</xref>. Our results show that freshly isolated brain mitochondria lacking <italic>Pink1</italic> undergo mPT at lower Ca<sup>2+</sup> concentrations than mitochondria from wildtype mice. Thus, it is likely that the facilitated Ca<sup>2+</sup>-induced mPT in <italic>Pink1</italic>-deficient mitochondria renders neurons in the brain more vulnerable to Ca<sup>2+</sup>-mediated death. Interestingly, we observed enhanced Ca<sup>2+</sup>-induced mitochondrial PTP opening with whole brain mitochondria, showing that this defect is not specific for the dopaminergic system. Because Ca<sup>2+</sup> plays an important role in the physiology of all neurons, this raises the question of how <italic>Pink1</italic> mutations in humans lead to the selective loss of DA neurons. An unusual aspect of adult dopaminergic neurons is that they express unique L-type Ca<sup>2+</sup> channels required for rhythmic pace-making and tonic DA release, and blocking Ca<sup>2+</sup> influx through these channels has been shown to protect against toxin-induced dopaminergic system degeneration in animal models of PD <xref ref-type="bibr" rid="pone.0016038-Chan1">[69]</xref>, <xref ref-type="bibr" rid="pone.0016038-Surmeier1">[70]</xref>. Therefore, the life-long reliance on L-type Ca<sup>2+</sup> channels may render DA neurons particularly vulnerable to perturbations in mitochondrial Ca<sup>2+</sup> buffering capacity. This hypothesis can be tested in future experiments with neurons derived from <italic>Pink1</italic>-deficient mice.</p>
      </sec>
      <sec id="s3b">
        <title>Increased JNK activity in the substantia nigra of <italic>Pink1<sup>−/−</sup></italic> mice</title>
        <p>We found that phosphorylated c-Jun accumulates in the substantia nigra of <italic>Pink1<sup>−/−</sup></italic> mice. Nuclear phospho-c-Jun was clearly surrounded by TH-positive cytosol in at least a proportion of the cells, suggesting that phospho-c-Jun is expressed in dopaminergic neurons. To further investigate this, we attempted colocalization of TH and phospho-c-Jun by confocal microscopy. However, phospho-c-Jun was not detectable with fluorescent secondary antibodies, while the highly sensitive nickel-enhanced DAB staining method was able to reveal phospho-c-Jun expression. We have observed that detection of at least one other protein, c-fos, is significantly more sensitive with the nickel-DAB method compared to fluorescent immunohistochemistry. Similar c-fos signals were obtained with a 50-fold higher dilution of the primary antibody (1∶15000) by the nickel-DAB method when compared to fluorescent detection (1∶300) (data not shown). As phospho-c-Jun was detected with 1∶300-diluted primary antibody only with the nickel-DAB method, we conclude that its expression is very weak. In the absence of confocal colocalization we cannot conclude with certainty that phospho-c-Jun is expressed within dopaminergic neurons of <italic>Pink1<sup>−/−</sup></italic> mice, although we believe this to be likely based on the data presented in <xref ref-type="fig" rid="pone-0016038-g005">Figure 5</xref>. We have not studied whether the phospho-c-Jun positive neurons express other markers such as neurogenin <xref ref-type="bibr" rid="pone.0016038-Gautier1">[18]</xref> and dopamine and cAMP-regulated phosphoproteins (DARPP-32), a regulator of DA-induced signal transduction <xref ref-type="bibr" rid="pone.0016038-Svenningsson2">[71]</xref>. Increased JNK signaling has been shown to promote dopaminergic neuron death <xref ref-type="bibr" rid="pone.0016038-Burke1">[22]</xref>, <xref ref-type="bibr" rid="pone.0016038-Levy1">[72]</xref>. Phospho-c-Jun has been detected in cytosolic granules adjacent to Lewy bodies in neurons in PD and dementia with Lewy bodies <xref ref-type="bibr" rid="pone.0016038-Ferrer1">[73]</xref>. Moreover, genetic deletion of specific JNK isoforms prevented complex I inhibitor (MPTP)-mediated <xref ref-type="bibr" rid="pone.0016038-Hunot1">[74]</xref> and axotomy-induced <xref ref-type="bibr" rid="pone.0016038-Brecht1">[75]</xref> cell death of nigral dopaminergic neurons in animal models of PD. These results suggest that JNK may be activated downstream of mitochondrial and possibly axonal damage in <italic>Pink1<sup>−/−</sup></italic> mice. In <italic>Drosophila</italic>, parkin deletion resulted in the activation of JNK in a small subgroup of dopaminergic neurons that underwent degeneration, suggesting that parkin negatively regulates JNK signaling <xref ref-type="bibr" rid="pone.0016038-Cha1">[26]</xref>. Because PINK1 kinase activity is required for many Parkin functions and Parkin acts downstream of PINK1 <xref ref-type="bibr" rid="pone.0016038-Narendra1">[11]</xref>, <xref ref-type="bibr" rid="pone.0016038-Bueler1">[14]</xref>, <xref ref-type="bibr" rid="pone.0016038-Ziviani1">[76]</xref>, increased JNK signaling in <italic>Pink1<sup>−/−</sup></italic> mice may in part be due to reduced Parkin activity. Taken together, these data implicate <italic>Pink1</italic> in the inhibition of JNK signaling and the mitigation of the effects of pro-apoptotic MAP kinase signaling.</p>
      </sec>
      <sec id="s3c">
        <title>Abnormal dopamine levels and turnover in the striatum of <italic>Pink1<sup>−/−</sup></italic> mice</title>
        <p>Importantly, we show that <italic>Pink1<sup>−/−</sup></italic> mice aged 6 months and older have significantly lower DA levels in the striatum than their wildtype controls. This is in contrast to another group that found DA levels to be normal in 8–9 month-old <italic>Pink1<sup>−/−</sup></italic> mice <xref ref-type="bibr" rid="pone.0016038-Kitada1">[16]</xref>. However, reduced DA levels were found in <italic>Pink1<sup>−/−</sup></italic> mice of independent origin at 9 and 22–24 months of age, although the dopaminergic neuron counts in the SNc were normal <xref ref-type="bibr" rid="pone.0016038-Gispert1">[17]</xref>. Our data are in agreement with the latter results. However, the <italic>Pink1<sup>−/−</sup></italic> mice described here show a significant decline in DA levels at a much earlier age than previously reported <xref ref-type="bibr" rid="pone.0016038-Gispert1">[17]</xref>. Furthermore, we show for the first time that DA turnover is increased in <italic>Pink1<sup>−/−</sup></italic> mice, providing a potential mechanism for the decline in DA in the absence of (significant) neuronal loss. It is well established that PD is characterized by increased DA turnover which occurs early in the disease <xref ref-type="bibr" rid="pone.0016038-Sossi1">[77]</xref>. Increased DA turnover is associated with elevated oxidative stress <xref ref-type="bibr" rid="pone.0016038-Spina1">[78]</xref>, which may exarcerbate dopaminergic dysfunction in the long-term. Thus, our studies suggest that abnormal DA homeostasis may precede and contribute to neuronal loss in <italic>Pink1</italic>-related Parkinsonism.</p>
      </sec>
      <sec id="s3d">
        <title>Transcriptional changes in the striatum of young <italic>Pink1<sup>−/−</sup></italic> mice indicate early dopaminergic dysfunction preceding dopamine loss</title>
        <p>Quantitative striatal gene expression analyses showed that the genes displaying altered expression in <italic>Pink1<sup>−/−</sup></italic> mice could be grouped into three categories. The first and largest category contained genes that regulate innate immune responses and/or apoptosis. Within this category, MKP-1, ATF3 and TRAIL-R2 were upregulated in <italic>Pink1<sup>−/−</sup></italic> mice. MKP-1 attenuates JNK-dependent apoptosis <xref ref-type="bibr" rid="pone.0016038-Wang1">[46]</xref> and is upregulated specifically in healthy but not degenerating neurons after axotomy, demonstrating that it participates in a neuronal stress response promoting survival <xref ref-type="bibr" rid="pone.0016038-Winter1">[79]</xref>. MKP-1 also acts as a negative regulator of innate immune responses by suppressing the expression of pro-inflammatory cytokines, endotoxic shock and activation of both p38 MAPK and JNK <xref ref-type="bibr" rid="pone.0016038-Salojin1">[80]</xref>, <xref ref-type="bibr" rid="pone.0016038-Chi1">[81]</xref>, <xref ref-type="bibr" rid="pone.0016038-Hammer1">[82]</xref>. Likewise, ATF3 and TRAIL-R2 are stress-inducible genes that reduce innate immune responses and tissue damage caused by chronic inflammation through their capacity to inhibit Toll-like receptor signaling <xref ref-type="bibr" rid="pone.0016038-Gilchrist1">[83]</xref>, <xref ref-type="bibr" rid="pone.0016038-Whitmore1">[84]</xref>, <xref ref-type="bibr" rid="pone.0016038-Diehl1">[85]</xref>, <xref ref-type="bibr" rid="pone.0016038-Finnberg1">[86]</xref>. In contrast, the expression of GSK-3β and both TNF receptors, which mediate pro-inflammatory signals, was suppressed in <italic>Pink1<sup>−/−</sup></italic> mice. Deficiency of TNF receptors inhibits microglial activation <xref ref-type="bibr" rid="pone.0016038-Sriram2">[87]</xref> and protects mice partially against MPTP-induced loss of dopaminergic terminals and DA decline <xref ref-type="bibr" rid="pone.0016038-Sriram1">[67]</xref>. The role of GSK-3β in innate immunity is complex and its effect on NF-κB function appears to depend on the cell type studied <xref ref-type="bibr" rid="pone.0016038-Hoeflich1">[88]</xref>, <xref ref-type="bibr" rid="pone.0016038-Graham1">[89]</xref>, <xref ref-type="bibr" rid="pone.0016038-Steinbrecher1">[90]</xref>. Reduced GSK-3β expression may be a protective adaptation to increased JNK signaling in <italic>Pink1<sup>−/−</sup></italic> mice, because GSK-3β inhibition has been shown to block pro-apoptotic JNK <xref ref-type="bibr" rid="pone.0016038-Takada1">[91]</xref>. On the other hand, GSK-3β also functions as a negative regulator of pro-inflammatory cytokine expression <xref ref-type="bibr" rid="pone.0016038-Martin1">[92]</xref>, <xref ref-type="bibr" rid="pone.0016038-Beurel1">[93]</xref> and decreased GSK-3β expression may render <italic>Pink1<sup>−/−</sup></italic> mice more vulnerable to TNF-α, IL-1β and LPS-induced brain inflammation <xref ref-type="bibr" rid="pone.0016038-Hoeflich1">[88]</xref>, <xref ref-type="bibr" rid="pone.0016038-Takada1">[91]</xref>, <xref ref-type="bibr" rid="pone.0016038-Vines1">[94]</xref>. However, it remains to be seen whether decreased GSK-3β expression is associated with altered GSK-3β activity in the striatum of <italic>Pink1<sup>−/−</sup></italic> mice. Overall, the genes identified in category 1 suggest that ablation of <italic>Pink1</italic> results in increased brain inflammation and MAP kinase pathway activation, possibly through heightened oxidative stress <xref ref-type="bibr" rid="pone.0016038-Martinon1">[95]</xref>, <xref ref-type="bibr" rid="pone.0016038-Gill1">[96]</xref>, <xref ref-type="bibr" rid="pone.0016038-Tansey1">[97]</xref>, <xref ref-type="bibr" rid="pone.0016038-Liu2">[98]</xref>. In response, <italic>Pink1<sup>−/−</sup></italic> mice appear to adapt the expression levels of critical genes controlling innate immune responses, perhaps to mitigate inflammation and inflammation-induced neuronal damage (see also below).</p>
        <p>Category 2 contained immediate-early transcription factors, including c-fos, FosB and Egr2, which were among the most highly overexpressed in the striatum of <italic>Pink1<sup>−/−</sup></italic> mice (<xref ref-type="table" rid="pone-0016038-t001">Table 1</xref>). The same genes were upregulated in the striatum of animals with toxin or surgery-induced dopaminergic deficits, or chronic alterations of dopaminergic neurotransmission, which depended on D1 and D2 DA receptor signaling <xref ref-type="bibr" rid="pone.0016038-Svenningsson1">[35]</xref>, <xref ref-type="bibr" rid="pone.0016038-Doucet1">[99]</xref>, <xref ref-type="bibr" rid="pone.0016038-Dragunow2">[100]</xref>. In addition, c-fos, FosB and Egr-2 were all upregulated by methamphetamine, which can cause long-lasting neurodegenerative effects that are at least in part due to activation of D1 DA receptors <xref ref-type="bibr" rid="pone.0016038-Beauvais1">[37]</xref>. Collectively, these results suggest increased DA receptor signaling in the striatum of <italic>Pink1</italic>-deficient mice, possibly as compensation to reduced DA neurotransmission. Consistent with this, reduced KCl-evoked DA release was described in acute striatal slices from 2–3 month-old <italic>Pink1<sup>−/−</sup></italic> mice previously <xref ref-type="bibr" rid="pone.0016038-Kitada1">[16]</xref>. Our results indicate that, in addition to evoked DA release, tonic DA release may also be affected in <italic>Pink1<sup>−/−</sup></italic> mice, leading to lasting elevations in postsynaptic striatal expression of immediate early genes. In addition Cyr61 was upregulated in <italic>Pink1<sup>−/−</sup></italic> mice. Cyr61 is an immediate-early gene induced downstream of JNK activation that has been implicated in neurodegeneration <xref ref-type="bibr" rid="pone.0016038-Kim2">[39]</xref>.</p>
        <p>Several genes of category 3 are induced in response to axonal injury and have been shown to promote axonal outgrowth and sprouting. In particular, overexpression of JunB and amphiregulin in the striatum of <italic>Pink1<sup>−/−</sup></italic> mice may be neuroprotective. JunB transgenic mice displayed significantly increased long-term survival of substantia nigra dopaminergic neurons after axotomy <xref ref-type="bibr" rid="pone.0016038-Winter2">[101]</xref>. Amphiregulin is a mitogen for adult neural stem cells <xref ref-type="bibr" rid="pone.0016038-Falk1">[42]</xref> and has been shown to promote axonal outgrowth <xref ref-type="bibr" rid="pone.0016038-Nilsson1">[43]</xref>. Several groups described that ATF3 stimulates axonal outgrowth and sprouting after neuronal injury <xref ref-type="bibr" rid="pone.0016038-Seijffers1">[102]</xref>, <xref ref-type="bibr" rid="pone.0016038-Pearson1">[103]</xref>, <xref ref-type="bibr" rid="pone.0016038-Saito1">[104]</xref>, <xref ref-type="bibr" rid="pone.0016038-Campbell1">[105]</xref>. Overexpression of ATF3 protected hippocampal neurons against excitotoxic cell death <xref ref-type="bibr" rid="pone.0016038-Francis1">[106]</xref> and PC12 cells against mutant huntingtin-induced toxicity <xref ref-type="bibr" rid="pone.0016038-Liang1">[107]</xref>. However, ATF3 has also been shown to promote cell death by mediating the apoptotic effects of p38 MAPK <xref ref-type="bibr" rid="pone.0016038-Lu1">[31]</xref>, and its expression preceded the death of spinal motor neurons and correlated with phosphorylation of c-Jun in a mouse model of familial amyotrophic laterals sclerosis <xref ref-type="bibr" rid="pone.0016038-Vlug1">[108]</xref>. Furthermore, it has been proposed that, in the nigrostriatal system, ATF3 and phospho-c-Jun participate in axotomy-induced neurodegeneration <xref ref-type="bibr" rid="pone.0016038-Song1">[109]</xref>. However, another study showed that ATF3 inhibits JNK-mediated neuron death through induction of Hsp27 expression and Akt activation <xref ref-type="bibr" rid="pone.0016038-Nakagomi1">[110]</xref>. Thus, an alternative interpretation is that ATF3 may be induced in response to increased JNK signaling to protect against neuron death. Overall, the changes in the expression of category 3 genes suggest the presence of axonal dysfunction and increased pro-apoptotic signaling in <italic>Pink1<sup>−/−</sup></italic> mice. This in turn may activate regenerative programs, including axonal sprouting and outgrowth, or activation and recruitment of neuronal stem cells that depend on JunB and amphiregulin.</p>
      </sec>
      <sec id="s3e">
        <title>Altered cytokine expression in the striatum of <italic>Pink1<sup>−/−</sup></italic> mice after peripheral inflammation</title>
        <p>As discussed above, upregulation of genes that antagonize innate immune responses suggests that compensatory gene expression may prevent neuroinflammation in <italic>Pink1</italic>-deficient mice. Consistent with this idea, we found that the expression levels of twelve cytokines measured by ELISA in the striatum were comparable between <italic>Pink1<sup>−/−</sup></italic> and wildtype mice. However, after peripheral LPS treatment <italic>Pink1<sup>−/−</sup></italic> mice expressed higher levels of striatal IL-1β, IL-10 and IL-12 than wildtype controls. Although not quite statistically significant, the levels of IL-2, IL-4 and TNF-α also tended to be higher in <italic>Pink1<sup>−/−</sup></italic> mice. Interestingly, IL-1β, TNF-α, IL-2 and IL-4 levels were shown to be elevated in the brain and cerebrospinal fluid in juvenile Parkinsonism and PD <xref ref-type="bibr" rid="pone.0016038-Mogi2">[111]</xref>, <xref ref-type="bibr" rid="pone.0016038-Mogi3">[112]</xref>, <xref ref-type="bibr" rid="pone.0016038-Mogi4">[113]</xref>. The same cytokines were also elevated in the serum of patients with idiopathic PD <xref ref-type="bibr" rid="pone.0016038-Brodacki1">[114]</xref>, <xref ref-type="bibr" rid="pone.0016038-Rentzos1">[115]</xref>. While higher levels of IL-10 may be protective in PD <xref ref-type="bibr" rid="pone.0016038-Rentzos1">[115]</xref>, <xref ref-type="bibr" rid="pone.0016038-Johnston1">[116]</xref>, <xref ref-type="bibr" rid="pone.0016038-Cadet1">[117]</xref>, the pro-inflammatory cytokines IL-1β and TNF-α have been shown to promote and exarcerbate DA neuron death <xref ref-type="bibr" rid="pone.0016038-Gayle1">[64]</xref>, <xref ref-type="bibr" rid="pone.0016038-Ferrari1">[65]</xref>, <xref ref-type="bibr" rid="pone.0016038-PottGodoy1">[66]</xref>, <xref ref-type="bibr" rid="pone.0016038-McCoy1">[68]</xref>, <xref ref-type="bibr" rid="pone.0016038-Wu1">[118]</xref>, <xref ref-type="bibr" rid="pone.0016038-Tansey2">[119]</xref>. Additionally, IL-12 may be involved in PD pathogenesis <xref ref-type="bibr" rid="pone.0016038-Rentzos1">[115]</xref>. Unlike wildtype microglia, cultured microglia isolated from neonatal <italic>Pink1<sup>−/−</sup></italic> mice responded with a significant increase in IL-10 secretion after LPS stimulation, in agreement with elevated levels of IL-10 in <italic>Pink1<sup>−/−</sup></italic> striatum. Unexpectedly, IL-1β secretion was not potentiated in microglia from either genotype and IL-12 expression was too low to be measured reliably. Nonetheless, the fact that other cytokines, including IL-6, TNF-α and G-CSF were highly induced by the LPS treatment showed that cultured microglia were competent to respond to an inflammatory stimulus. However, the results also suggest that <italic>in vitro</italic> cultured neonatal microglia may not fully mirror the capacity and cytokine profile of adult brain microglia when stimulated with LPS. Although T cells can also synthesize cytokines, we favor the idea that microglial cells are responsible for the increased cytokine expression in the brain, as brain microglial cells strongly respond to LPS via Toll-like receptor activation <xref ref-type="bibr" rid="pone.0016038-Rivest1">[63]</xref>. In fact, significant up-regulation of various cytokine mRNAs in the striatum was shown to occur as shortly as four hours after peripheral injection of a LPS dose comparable to that used in our studies <xref ref-type="bibr" rid="pone.0016038-Krzyszton1">[120]</xref>. In contrast, T cells are present in very low numbers in the brain and part of the antigen-specific adaptive immune response, which takes longer to develop than the short time between LPS injection and cytokine analysis in our experiments (eight hours). Real-time PCR analysis of CD3 expression confirmed that this T cell marker is barely detectable in the striatum and its levels also did not increase after LPS injection. Among the brain resident cells, astrocytes are also known to secrete cytokines, including IL-1β and TNF-α in response to LPS <xref ref-type="bibr" rid="pone.0016038-Lin1">[121]</xref>. Our experiments have not addressed a possible role of astrocytes in cytokine production. Future studies with microglia and mixed astrocytes/microglia cultures from the adult brain are needed to determine whether microglia can fully recapitulate the altered cytokine profile observed in the brain after LPS injection, or whether astrocytes may be involved as well. Because peripheral LPS increased the expression of both pro-inflammatory (IL-1β and IL-12) and anti-inflammatory (IL-10) cytokines in <italic>Pink1<sup>−/−</sup></italic> mice, the net effect on neuronal survival is difficult to predict. However, as <italic>Pink1</italic> defects cause PD in humans, a plausible and testable hypothesis is that abnormal cytokine regulation in the brain of <italic>Pink1<sup>−/−</sup></italic> mice enhances the vulnerability to inflammation-induced DA neuron death. Interestingly, Parkin-deficient mice treated for 3–6 months with repeated, low doses of systemic LPS developed subtle fine-motor deficits and DA neuron loss that were more pronounced than in wildtype controls <xref ref-type="bibr" rid="pone.0016038-FrankCannon1">[122]</xref>, indicating that enhanced neuronal vulnerability to inflammation may play a role in recessive Parkinsonism.</p>
      </sec>
      <sec id="s3f">
        <title>Impaired basal and inflammatory cytokine-induced NF-κB signaling in <italic>Pink1<sup>−/−</sup></italic> embryonic fibroblasts</title>
        <p>The transcription factor NF-κB has many roles in the regulation of cell survival, apoptosis and innate immunity <xref ref-type="bibr" rid="pone.0016038-Rivest1">[63]</xref>. NF-κB is a key regulator of inflammatory gene expression in microglial cells, which can cause brain inflammation when excessively activated <xref ref-type="bibr" rid="pone.0016038-Rivest1">[63]</xref>. However, NF-κB is also an important survival factor for neurons and often induces genes favoring survival <xref ref-type="bibr" rid="pone.0016038-Mattson1">[123]</xref>. For example, NF-κB is required for TNF-α induced expression of the neuroprotective genes Bcl-2 and Bcl-x in primary hippocampal neurons <xref ref-type="bibr" rid="pone.0016038-Tamatani1">[124]</xref> and protects neurons against glucose deprivation, calcium-induced cell death and oxidative stress <xref ref-type="bibr" rid="pone.0016038-Cheng1">[125]</xref>, <xref ref-type="bibr" rid="pone.0016038-Mattson2">[126]</xref>. Our results show that, compared to wildtype MEF, basal and TNF-α induced NF-κB activity is reduced in fibroblasts derived from <italic>Pink1<sup>−/−</sup></italic> mice. Moreover, we found that NF-κB activation in response to IL-1β and LPS is also impaired in <italic>Pink1<sup>−/−</sup></italic> MEF. Taken together, these results show a deficit of <italic>Pink1<sup>−/−</sup></italic> embryonic fibroblasts in NF-κB signaling induced by cytokines, and suggest that <italic>Pink1</italic> deficiency may predispose neurons to inflammation and oxidative stress-induced apoptosis <italic>in vivo</italic>. Consistent with this, it has recently been shown that <italic>Pink1</italic> enhances NF-κB activation by phosphorylation of Parkin <xref ref-type="bibr" rid="pone.0016038-Sha1">[127]</xref>. It should be noted that one group reported that selective inhibition of NF-κB activation reduced MPTP-induced dopaminergic degeneration in the sporadic mouse model of PD <xref ref-type="bibr" rid="pone.0016038-Ghosh1">[128]</xref>. However, another group concluded that NF-κB plays no role in MPTP-induced DA neuron loss <xref ref-type="bibr" rid="pone.0016038-Teismann1">[129]</xref>. Further studies with <italic>Pink1<sup>−/−</sup></italic> mice will reveal whether abnormal NF-κB signaling renders these mice more or less susceptible to exogenous stress-induced DA neuron loss.</p>
      </sec>
      <sec id="s3g">
        <title>Conclusions</title>
        <p>In conclusion, our results show that ablation of <italic>Pink1</italic> generates a valuable preclinical model of PD in mice, showing some of the cardinal features of PD including reduced levels of DA and increased DA turnover. These defects are preceded by early transcriptional changes indicative of dopaminergic neuron dysfunction, which may be caused by alterations in mitochondrial Ca<sup>2+</sup> buffering capacity as well as increased JNK signaling in the substantia nigra. In addition, lack of <italic>Pink1</italic> reduces basal and cytokine-induced NF-κB signaling and increases the levels of both pro-inflammatory and anti-inflammatory cytokines after peripheral LPS challenge. This may lead to decreased neuroprotection against a variety of stresses <xref ref-type="bibr" rid="pone.0016038-Mattson1">[123]</xref>, <xref ref-type="bibr" rid="pone.0016038-Mattson2">[126]</xref>, <xref ref-type="bibr" rid="pone.0016038-Fridmacher1">[130]</xref>, <xref ref-type="bibr" rid="pone.0016038-Turrin1">[131]</xref>, <xref ref-type="bibr" rid="pone.0016038-Marchetti1">[132]</xref>, impaired repair after brain injury <xref ref-type="bibr" rid="pone.0016038-Arnett1">[133]</xref>, <xref ref-type="bibr" rid="pone.0016038-Mason1">[134]</xref>, reduced response to neurotrophic factors <xref ref-type="bibr" rid="pone.0016038-Cao1">[135]</xref> and/or increased vulnerability to inflammation-induced DA neuron loss due to an imbalance between pro-inflammatory and anti-inflammatory mediators <xref ref-type="bibr" rid="pone.0016038-Gayle1">[64]</xref>, <xref ref-type="bibr" rid="pone.0016038-Ferrari1">[65]</xref>, <xref ref-type="bibr" rid="pone.0016038-PottGodoy1">[66]</xref>, <xref ref-type="bibr" rid="pone.0016038-Sriram1">[67]</xref>, <xref ref-type="bibr" rid="pone.0016038-McCoy1">[68]</xref>. The differential gene expression profile observed in the striatum of <italic>Pink1</italic>-deficient mice is compatible with neuroprotective adaptations to increased MAP kinase signaling and inflammation in the <italic>Pink1<sup>−/−</sup></italic> brain. Experiments aimed to eliminate or over-express selected genes that are altered in <italic>Pink1<sup>−/−</sup></italic> mice will ultimately lead to improved animal models for recessive Parkinsonism and the identification of genes and pathways that could serve as targets for future PD therapy.</p>
      </sec>
    </sec>
    <sec id="s4" sec-type="materials|methods">
      <title>Materials and Methods</title>
      <p>All animal work has been conducted according to national and international guidelines and has been approved by the Animal Care and Use Committee of the University of Kentucky with identification number 2009-0453. The current approval is valid until 3/9/2011.</p>
      <sec id="s4a">
        <title>Generation of <italic>Pink1<sup>−/−</sup></italic> mice</title>
        <p>A DNA fragment corresponding to nucleotides 3086-12111 of the mouse <italic>Pink1</italic> locus (Genbank accession NC_000070.5) was amplified by PCR from mouse genomic DNA using a high-fidelity DNA polymerase. The PCR product was subcloned into the vector pGEM-T Easy (Promega) and the entire insert was sequenced and its sequence was found to be identical with the published Genbank entry. Subsequently, a 2011 bp internal fragment spanning <italic>Pink1</italic> nucleotides 7579 (intron 3) to 9590 (intron 5) was excised, removing <italic>Pink1</italic> exons 4 and 5. This fragment was replaced with a PGK-neo-pA cassette amplified by PCR from plasmid ploxPFLPneo (Dr. James Shayman, University of Michigan Medical School). 10<sup>7</sup> AB2.2 mouse ES cells (129/Sv) were electroporated with 30 µg linearized targeting vector and plated in ES-DMEM/15% ES-qualified FCS at 1−2×10<sup>6</sup> cells into 10-cm plates containing mitomycin C-inactivated primary mouse embryonic fibroblasts. G418-resistant ES cell colonies were picked individually at day 10 of selection (0.4 mg/ml G418) and clones with a targeted <italic>Pink1</italic> gene were identified by PCR with primer P1 (5′-attgctgaagagcttggcggcgaatgggct-3′) located in the neo gene and primer P2 (5′-tgc tgactgctgcaagagccaggcgatca-3′) located in <italic>Pink1</italic> exon 8 adjacent to the 3′ end of the targeting vector (shown in <xref ref-type="fig" rid="pone-0016038-g001">Figure 1</xref>). After confirmation of correct targeting vector insertion at both 5′ and 3′ junctions and ruling out additional random insertions by Southern blot analyses, ES cells from two different clones were injected into C57BL/6 blastocysts. Both clones yielded highly chimeric offspring that were crossed to 129/Sv;C57BL/6 F1 hybrid mice to generate F1 heterozygous mutant mice. The latter were then intercrossed to obtain homozygous mutant and wildtype mice for experiments.</p>
      </sec>
      <sec id="s4b">
        <title>Southern blots and <italic>Pink1</italic> transcript analysis in mice</title>
        <p>10–20 µg genomic DNA from the tails of mice was digested with the indicated restriction enzymes and analyzed by Southern blot using a-P<sup>32</sup>-dCTP labeled random-primed DNA probes (Stratagene Prime-It II kit). Total brain RNA was isolated with the RiboPure kit (Ambion) and converted to cDNA with the Superscript III kit (Invitrogen). Quantitative real-time PCR (Q-PCR) for exon 4-containing transcripts was done with primers 5′-gcgaagccatcttaagcaaa-3′ (exon 3 forward) and 5′-agtagtgtgggggcagcata-3′ (exon 4 reverse). Q-PCR for transcripts encompassing exons 1-3 was done with primers 5′-atccagaggcagttcatggt-3′ (exon 1 forward) and 5′-ttaagatggcttcgctggag-3′ (exon 3 reverse). <italic>Pink1</italic> transcript levels were normalized to 18S rRNA levels detected in the same samples. PCR to detect alternative splicing events was done with forward primers located in exon 3 (5′-ggctggagagtatggagcag-3′ and 5′-agcgaagccatcttaagc aa-3′) and reverse primers located in exon 6 (5′-ccaccacgctctacactgg-3′), exon 7 (5′-caggtatcggct ttgctgta-3′) and exon 8 (5′-ccaggttagccagaaacagc-3′).</p>
      </sec>
      <sec id="s4c">
        <title>Quantitative gene expression analysis with PCR arrays</title>
        <p>Total RNA was isolated from the striatum of mice with the RiboPure kit (Ambion). RNA quality was analyzed on RNA 6000 NanoLab Chips in the Agilent Bioanalyzer 2000 (Agilent Technologies) of the University of Kentucky Microarray Facility. Only RNAs with an RNA integrity number of at least 9 (on a scale of 0–10) were used for analysis. One µg total RNA was converted to cDNA using the RT<sup>2</sup> first strand synthesis kit (SA Biosciences, MD) and the cDNA reaction was brought to a final volume of 111 µl with H<sub>2</sub>O. 102 µl diluted cDNA reaction was mixed with 2x RT<sup>2</sup> qPCR Master Mix (SA Biosciences) and H<sub>2</sub>O to reach a final volume of 2.7 ml. 25 µl of the mixture was added into each of the wells of the RT<sup>2</sup> Profiler PCR Arrays (SA Biosciences) and PCR was carried out on the Roche480 Cycler using a cycling program optimized for PCR arrays (SA Biosciences). Each PCR array contained 84 transcripts of the corresponding signaling pathway, a set of five housekeeping genes as internal controls and additional controls for efficiency of reverse transcription, PCR and the absence of contaminating genomic DNA. Data were analyzed with the ΔΔCt method using the PCR Array Data Analysis Web Portal (SA Biosciences), which includes quality control for each PCR run/array.</p>
      </sec>
      <sec id="s4d">
        <title>Measurement of mitochondrial Ca<sup>2+</sup> load capacity and permeability transition</title>
        <p>Mitochondria were isolated from whole brains of 8-week old male wildtype or <italic>Pink1<sup>−/−</sup></italic> mice as described previously <xref ref-type="bibr" rid="pone.0016038-Sullivan1">[136]</xref>. Briefly, brains were homogenized in 2 ml ice-cold isolation buffer (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, 1 mM EGTA, pH 7.2). Homogenates were centrifuged twice at 1,300 <italic>g</italic> for 3 min and then at 13,000 <italic>g</italic> for 10 min at 4°C, using the supernatants and filling up to a final volume of 2 ml with isolation buffer after each centrifugation. The final pellet was resuspended in 0.5 ml isolation buffer and the cells were disrupted in a nitrogen cell disruption bomb (model 4639, Parr Instruments, IL) at 1200 psi for 10 min at 4°C. The resultant crude mitochondrial fraction was placed onto a discontinuous Ficoll gradient (2 ml 7.5% Ficoll solution layered on top of 2 ml 10% Ficoll solution) and centrifuged at 100,000 <italic>g</italic> for 30 min at 4°C. The resulting mitochondrial pellet was carefully separated, resuspended and washed with isolation buffer (without EGTA). After another centrifugation for 10 min at 10,000 <italic>g</italic>, the pellet was resuspended in isolation buffer (without EGTA) and stored on ice until analysis. This method yielded highly coupled mitochondria with RCR of 14.5±2.1 and 12.5±1.9 for wildtype and <italic>Pink1<sup>−/−</sup></italic> mice (n = 7 preparations). Mitochondrial protein content was measured with the BCA protein assay kit (Pierce, IL). Purified mitochondria (100 µg protein/ml) were placed in constantly stirred, temperature-controlled (37°C) cuvettes in 2 ml respiration buffer (125 mM KCl, 0.1% BSA, 20 mM HEPES, 2 mM MgCl<sub>2</sub> and 2.5 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.2), which contained 100 nM calcium green-5N hexapotassium salt (CaG5N) (Molecular Probes, ex506 nm, em532 nm) and 100 nM tetramethylrhodamine (TMRE) (Molecular Probes, ex550 nm, em575 nm) to monitor extra-mitochondrial calcium content and changes in mitochondrial membrane potential (ΔΨ<sub>M</sub>), respectively. Because CaG5N is an indicator of the <italic><underline>extra</underline></italic>-mitochondrial calcium concentration and not imported into mitochondria, data are not confounded by possible differences in the dye loading capacity between wildtype and <italic>Pink1<sup>−/−</sup></italic> mitochondria. Scans began with a baseline reading followed by addition of mitochondrial substrates (5 mM pyruvate and 2.5 mM malate) at 1 min, 150 mM ADP at 2 min and 1 mM oligomycin at 3 min. At 5 min, calcium chloride (32 mM) was infused gradually through an infusion pump (model 310, KD Scientific, MA) at a rate of 160 nmol per mg protein per minute until the mitochondria were no longer able to sequester calcium, as indicated by a rapid rise in CaG5N signal and loss of ΔΨ<sub>M</sub>. The chemical uncoupler carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) was added as a positive control at the end of each run. In some experiments the PTP inhibitor CsA (1 µM) was added at the start of the experiment and was shown to increase Ca<sup>2+</sup> loading capacity. The maximum calcium storage capacity of each mitochondrial preparation was quantified as previously described <xref ref-type="bibr" rid="pone.0016038-Brown1">[25]</xref>.</p>
      </sec>
      <sec id="s4e">
        <title>NF-κB activity assay in mouse embryonic fibroblasts</title>
        <p>Mouse embryonic fibroblasts (MEF) were prepared from wildtype and <italic>Pink1<sup>−/−</sup></italic> embryos at 15.5–16.5 dpc as described (Nagy <italic>et al</italic>., 2003: Manipulating the Mouse Embryo, 3<sup>rd</sup> edition, CSHL Press). Cells were grown in DMEM, 10% fetal bovine serum (FBS) supplemented with penicillin/streptomycin, 0.2 mM L-glutamine and 0.1 mM 2-mercaptoethanol (all from Invitrogen) in a 37°C incubator with 5% CO<sub>2</sub>. For experiments, cells were plated in 24-well plates at 50,000 cells per well and transfected the next day in fresh medium with 800 ng pNF-κB-luc plasmid (Clontech) mixed with 1.6 µl lipofectamine LTX and PLUS reagent prepared in OPTI-MEM (all from Invitrogen). Comparable transfection efficiencies were confirmed with pEGFP-N1 plasmid (Clontech). For each condition wildtype and <italic>Pink1<sup>−/−</sup></italic> cells were transfected with the same DNA/lipofectamine mixture. 24 hours after transfection, medium was changed and cells were stimulated with 10 ng/ml IL-1β, 30 ng/ml TNF-α (R&amp;D Systems, MN) or 100 ng/ml LPS from <italic>Salmonella minnesota</italic> (Sigma, MO). Eight hours after stimulation cells were lysed in cell culture lysis buffer and luciferase activity measured with the luciferase reporter assay system (Promega, WI). Luminescence was measured in a luminometer (TD-20/20, Turner Design, Promega) and normalized to total protein present in each sample (determined with BCA kit). Comparable transfection efficiency was confirmed by quantification of EGFP-positive cells in several wells of wildtype and <italic>Pink1<sup>−/−</sup></italic> MEF transfected in parallel in the same experiments, using images taken with an Axiovert 40 fluorescence microscope (Carl Zeiss, Germany) and analyzed with AxioVision software version 4.8 (Carl Zeiss, Germany).</p>
      </sec>
      <sec id="s4f">
        <title>Expression of phospho-c-Jun and TH in the substantia nigra</title>
        <p>Brains from eight-week old wildtype and <italic>Pink1<sup>−/−</sup></italic> mice were fixed in 4% paraformaldehyde for 48 hrs at 4°C followed by slow immersion in 30% (w/v) sucrose in PBS for 4 days. Thirty µm-thick sections were prepared with a sliding freezing microtome (Microm, Germany) and stored in cryopreservation solution (30% (w/v) sucrose, 1% (w/v) polyvinylpyrrolidone, 30% ethylene glycol, 100 mM sodium phosphate buffer, pH 7.2). Sections containing the substantia nigra were washed in Tris-buffered saline (TBS) and blocked in 5% donkey serum, 0.2% BSA, 0.3% Triton X-100, 0.01% sodium azide in TBS for one hour at room temperature (RT). Sections were incubated overnight at RT with 1∶300 diluted phospho-c-Jun antibody (Cell Signaling, MA) in 2% donkey serum, 0.2% BSA, 0.15% Triton X-100, 0.01% sodium azide. After three washes in TBS the sections were incubated for 1 hour at RT with 1∶500-diluted biotin-SP-conjugated donkey anti-rabbit IgG (Jackson Immunoresearch) in 2% donkey serum, 0.2% BSA in TBS. After washing as above sections were incubated in freshly prepared, filtered nickel-diaminobenzidine (nickel-DAB) solution (1.5g nickel ammonium sulfate, 25 mg DAB in 400 ml of 0.1 M sodium acetate buffer). Prior to use 2 µl of 30% hydrogen peroxide was added to the nickel-DAB solution. Color development in the sections (placed on a shaker) was monitored and the reaction was stopped before background developed in control sections incubated with secondary antibody only. Subsequently, the same sections were used to identify TH-expressing neurons by fluorescent IHC. For this purpose sections were washed in TBS, re-blocked for 20 min in blocking buffer and incubated overnight at 4°C with 1∶1500 diluted sheep anti-TH antibody (Pel-Freeze, AR). 1∶500 diluted DyLight549-conjugated anti-sheep IgG (Invitrogen) was used for 1 hour at RT as the secondary antibody. After extensive washing in TBS, sections were mounted with Permount (Fisher Scientific, NJ) and images captured through phase-contrast (phospho-c-Jun) or fluorescent filters (TH) using an Axiovert 40 microscope equipped with an AxioCam MRc5 digital camera and AxioVision software (Carl-Zeiss, Germany).</p>
      </sec>
      <sec id="s4g">
        <title>Measurement of cytokines in the striatum and medium of isolated cultured microglia cells</title>
        <p>Six month-old mice were left untreated or given intra-peritoneal (i.p.) injections of 0.33 µg LPS from <italic>Salmonella minnesota</italic> per gram body weight. Eight hours after injection mice were euthanized and brains harvested. Dose of LPS and time of analysis were chosen based on a previous publication <xref ref-type="bibr" rid="pone.0016038-Krzyszton1">[120]</xref>. The striatum was dissected from each brain on ice and homogenized with T-PER tissue protein extraction reagent (Pierce Biotechnology, IL) containing protease inhibitor cocktail (Sigma, MO) (20 ml buffer/mg tissue). Homogenates were centrifuged (10,000 g, 5 min, 4°C) and supernatants collected and stored at −80°C until analysis. Cytokines in the striatal lysates (100 µg total protein) were measured using Multi-Analyte ELISArray plates (SA Biosciences, MD) according to the manufacturer's instructions. The plates allow for the simultaneous relative quantification of IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IL-17α, interferon-γ, TNF-α, G-CSF and GM-CSF. Primary microglia cultures were prepared from the cerebral cortices of neonatal (1 day-old) wildtype and <italic>Pink1<sup>−/−</sup></italic> mice as previously described for rats <xref ref-type="bibr" rid="pone.0016038-Akundi1">[137]</xref>. Briefly, forebrains were cleared from meninges, minced and gently dissociated by repeated pipetting in PBS followed by filtration through a 70-µm cell strainer (Falcon). Cells were collected by centrifugation (1000 rpm, 10 min), resuspended in DMEM containing 10% fetal calf serum and antibiotics (40 U/ml penicillin and 40 µg/ml streptomycin), and cultured on 10-cm cell culture dishes (1.3×10<sup>5</sup> cells/cm<sup>2</sup>) in 5% CO<sub>2</sub> at 37°C. Floating microglia, collected by shaking cultures at 90 rpm for 5 min, were harvested every week (between 2–7 weeks) and re-seeded into wells of a 24-well plate to give pure microglial cultures. For experiments, cultures were washed to remove non-adherent cells and fresh medium was added. Cells (n = 8 wells/condition) were treated with 100 ng/ml LPS (Sigma) or left untreated for 24 h. Supernatants were collected, clarified by centrifugation and used to quantify cytokines as described above.</p>
      </sec>
      <sec id="s4h">
        <title>Quantification of striatal catecholamines and nigral dopaminergic neurons</title>
        <p>Striatal tissue was dissected on an-ice-cold plate, tissue pieces weighed and snap-frozen in liquid nitrogen. Samples were homogenized in 300 µl of ice-cold 0.1 M perchloric acid containing the internal standard dihydroxybenzylamine and centrifuged for 5 min at 15,000× <italic>g</italic>. Supernatants were filtered through a 0.22 µm pore size membrane and diluted with HPLC mobile phase prior to injection onto the HPLC column. Striatal tissue levels of DA, 3, 4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured by reverse phase HPLC coupled to electrochemical detection as described <xref ref-type="bibr" rid="pone.0016038-Cass1">[138]</xref>. TH-positive neurons in 30 µm-thick sections of the substantia nigra were stained with a sheep anti-TH antibody (Pel-Freeze) and detected with biotinylated secondary antibody and the DAB method as described by us previously <xref ref-type="bibr" rid="pone.0016038-Dong1">[139]</xref>, <xref ref-type="bibr" rid="pone.0016038-Paterna1">[140]</xref>. The optical fractionator <xref ref-type="bibr" rid="pone.0016038-West1">[141]</xref>, <xref ref-type="bibr" rid="pone.0016038-Harding1">[142]</xref> and dissector method for unbiased stereological cell counting was used to estimate the numbers of dopaminergic neurons using the Stereologer System and software (Stereology Research Center, <ext-link ext-link-type="uri" xlink:href="http://www.disector.com" xlink:type="simple">www.disector.com</ext-link>). Five wildtype and six <italic>Pink1<sup>−/−</sup></italic> mice were analyzed and neurons in every fourth section of the SNc were counted (12 sections per mouse, both hemispheres).</p>
      </sec>
      <sec id="s4i">
        <title>Data analysis and statistics</title>
        <p>Data were analyzed using the Student's t-test. Results are expressed as mean ± standard deviation. PCR Array data were analyzed using the ΔΔC<sub>t</sub> method and the web tools of SA Biosciences (<ext-link ext-link-type="uri" xlink:href="http://www.sabiosciences.com/pcr/arrayanalysis.php" xlink:type="simple">http://www.sabiosciences.com/pcr/arrayanalysis.php</ext-link>).</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Lisa Boock for technical assistance during ES cell screening and Laura Peters for help with HPLC analyses, Dr. Allan Bradley (Wellcome Trust Sanger Institute, Cambridge, UK) for AB2.2 ES cells and Dr. James Shayman (University of Michigan Medical School) for the plasmid ploxPFLPneo. We are grateful to Dr. Stephen Scheff (Sanders Brown Center on Aging, University of Kentucky) for instructions and theory on unbiased stereology and providing access to equipment required for cell counting.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0016038-Valente1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Valente</surname><given-names>EM</given-names></name><name name-style="western"><surname>Abou-Sleiman</surname><given-names>PM</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>V</given-names></name><name name-style="western"><surname>Muqit</surname><given-names>MM</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>K</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Hereditary early-onset Parkinson's disease caused by mutations in PINK1.</article-title>             <source>Science</source>             <volume>304</volume>             <fpage>1158</fpage>             <lpage>1160</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Bonifati1">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bonifati</surname><given-names>V</given-names></name><name name-style="western"><surname>Rohe</surname><given-names>CF</given-names></name><name name-style="western"><surname>Breedveld</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Fabrizio</surname><given-names>E</given-names></name><name name-style="western"><surname>De Mari</surname><given-names>M</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes.</article-title>             <source>Neurology</source>             <volume>65</volume>             <fpage>87</fpage>             <lpage>95</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Valente2">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Valente</surname><given-names>EM</given-names></name><name name-style="western"><surname>Salvi</surname><given-names>S</given-names></name><name name-style="western"><surname>Ialongo</surname><given-names>T</given-names></name><name name-style="western"><surname>Marongiu</surname><given-names>R</given-names></name><name name-style="western"><surname>Elia</surname><given-names>AE</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>PINK1 mutations are associated with sporadic early-onset parkinsonism.</article-title>             <source>Ann Neurol</source>             <volume>56</volume>             <fpage>336</fpage>             <lpage>341</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Silvestri1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Silvestri</surname><given-names>L</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>V</given-names></name><name name-style="western"><surname>Bellacchio</surname><given-names>E</given-names></name><name name-style="western"><surname>Atorino</surname><given-names>L</given-names></name><name name-style="western"><surname>Dallapiccola</surname><given-names>B</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism.</article-title>             <source>Hum Mol Genet</source>             <volume>14</volume>             <fpage>3477</fpage>             <lpage>3492</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Pridgeon1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pridgeon</surname><given-names>JW</given-names></name><name name-style="western"><surname>Olzmann</surname><given-names>JA</given-names></name><name name-style="western"><surname>Chin</surname><given-names>LS</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group>             <year>2007</year>             <article-title>PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1.</article-title>             <source>PLoS Biol</source>             <volume>5</volume>             <fpage>e172</fpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Clark1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>IE</given-names></name><name name-style="western"><surname>Dodson</surname><given-names>MW</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C</given-names></name><name name-style="western"><surname>Cao</surname><given-names>JH</given-names></name><name name-style="western"><surname>Huh</surname><given-names>JR</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin.</article-title>             <source>Nature</source>             <volume>441</volume>             <fpage>1162</fpage>             <lpage>1166</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Park1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SB</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>S</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin.</article-title>             <source>Nature</source>             <volume>441</volume>             <fpage>1157</fpage>             <lpage>1161</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Yang1">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gehrke</surname><given-names>S</given-names></name><name name-style="western"><surname>Imai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>Y</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>103</volume>             <fpage>10793</fpage>             <lpage>10798</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Poole1">
        <label>9</label>
        <element-citation publication-type="other" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Poole</surname><given-names>AC</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>RE</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>LA</given-names></name><name name-style="western"><surname>McBride</surname><given-names>HM</given-names></name><name name-style="western"><surname>Whitworth</surname><given-names>AJ</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>The PINK1/Parkin pathway regulates mitochondrial morphology.</article-title>             <publisher-name>Proc Natl Acad Sci U S A</publisher-name>          </element-citation>
      </ref>
      <ref id="pone.0016038-Kim1">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Song</surname><given-names>S</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>SK</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>PINK1 controls mitochondrial localization of Parkin through direct phosphorylation.</article-title>             <source>Biochem Biophys Res Commun</source>             <volume>377</volume>             <fpage>975</fpage>             <lpage>980</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Narendra1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Narendra</surname><given-names>DP</given-names></name><name name-style="western"><surname>Jin</surname><given-names>SM</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>A</given-names></name><name name-style="western"><surname>Suen</surname><given-names>DF</given-names></name><name name-style="western"><surname>Gautier</surname><given-names>CA</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>PINK1 is selectively stabilized on impaired mitochondria to activate Parkin.</article-title>             <source>PLoS Biol</source>             <volume>8</volume>             <fpage>e1000298</fpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-VivesBauza1">
        <label>12</label>
        <element-citation publication-type="other" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Vives-Bauza</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cui</surname><given-names>M</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>RL</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>PINK1-dependent recruitment of Parkin to mitochondria in mitophagy.</article-title>             <publisher-name>Proc Natl Acad Sci U S A</publisher-name>          </element-citation>
      </ref>
      <ref id="pone.0016038-Geisler1">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Geisler</surname><given-names>S</given-names></name><name name-style="western"><surname>Holmstrom</surname><given-names>KM</given-names></name><name name-style="western"><surname>Skujat</surname><given-names>D</given-names></name><name name-style="western"><surname>Fiesel</surname><given-names>FC</given-names></name><name name-style="western"><surname>Rothfuss</surname><given-names>OC</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1.</article-title>             <source>Nat Cell Biol</source>             <volume>12</volume>             <fpage>119</fpage>             <lpage>131</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Bueler1">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bueler</surname><given-names>H</given-names></name></person-group>             <year>2010</year>             <article-title>Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease.</article-title>             <source>Apoptosis</source>             <volume>15</volume>             <fpage>1336</fpage>             <lpage>1353</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Dagda1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dagda</surname><given-names>RK</given-names></name><name name-style="western"><surname>Chu</surname><given-names>CT</given-names></name></person-group>             <year>2009</year>             <article-title>Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis.</article-title>             <source>J Bioenerg Biomembr</source>             <volume>41</volume>             <fpage>473</fpage>             <lpage>479</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Kitada1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kitada</surname><given-names>T</given-names></name><name name-style="western"><surname>Pisani</surname><given-names>A</given-names></name><name name-style="western"><surname>Porter</surname><given-names>DR</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Tscherter</surname><given-names>A</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>104</volume>             <fpage>11441</fpage>             <lpage>11446</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Gispert1">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gispert</surname><given-names>S</given-names></name><name name-style="western"><surname>Ricciardi</surname><given-names>F</given-names></name><name name-style="western"><surname>Kurz</surname><given-names>A</given-names></name><name name-style="western"><surname>Azizov</surname><given-names>M</given-names></name><name name-style="western"><surname>Hoepken</surname><given-names>HH</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration.</article-title>             <source>PLoS One</source>             <volume>4</volume>             <fpage>e5777</fpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Gautier1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gautier</surname><given-names>CA</given-names></name><name name-style="western"><surname>Kitada</surname><given-names>T</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name></person-group>             <year>2008</year>             <article-title>Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>105</volume>             <fpage>11364</fpage>             <lpage>11369</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Dagda2">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dagda</surname><given-names>RK</given-names></name><name name-style="western"><surname>Cherra</surname><given-names>SJ</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Kulich</surname><given-names>SM</given-names></name><name name-style="western"><surname>Tandon</surname><given-names>A</given-names></name><name name-style="western"><surname>Park</surname><given-names>D</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Loss of PINK1 Function Promotes Mitophagy through Effects on Oxidative Stress and Mitochondrial Fission.</article-title>             <source>J Biol Chem</source>             <volume>284</volume>             <fpage>13843</fpage>             <lpage>13855</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Cherra1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cherra</surname><given-names>SJ</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Dagda</surname><given-names>RK</given-names></name><name name-style="western"><surname>Tandon</surname><given-names>A</given-names></name><name name-style="western"><surname>Chu</surname><given-names>CT</given-names></name></person-group>             <year>2009</year>             <article-title>Mitochondrial autophagy as a compensatory response to PINK1 deficiency.</article-title>             <source>Autophagy</source>             <volume>5</volume>          </element-citation>
      </ref>
      <ref id="pone.0016038-WoodKaczmar1">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wood-Kaczmar</surname><given-names>A</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>S</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Abramov</surname><given-names>AY</given-names></name><name name-style="western"><surname>Miljan</surname><given-names>EA</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons.</article-title>             <source>PLoS One</source>             <volume>3</volume>             <fpage>e2455</fpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Burke1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Burke</surname><given-names>RE</given-names></name></person-group>             <year>2007</year>             <article-title>Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease.</article-title>             <source>Pharmacol Ther</source>             <volume>114</volume>             <fpage>261</fpage>             <lpage>277</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Weihofen1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Weihofen</surname><given-names>A</given-names></name><name name-style="western"><surname>Ostaszewski</surname><given-names>B</given-names></name><name name-style="western"><surname>Minami</surname><given-names>Y</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group>             <year>2008</year>             <article-title>Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1.</article-title>             <source>Hum Mol Genet</source>             <volume>17</volume>             <fpage>602</fpage>             <lpage>616</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Gandhi1">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>S</given-names></name><name name-style="western"><surname>Wood-Kaczmar</surname><given-names>A</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Plun-Favreau</surname><given-names>H</given-names></name><name name-style="western"><surname>Deas</surname><given-names>E</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death.</article-title>             <source>Mol Cell</source>             <volume>33</volume>             <fpage>627</fpage>             <lpage>638</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Brown1">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>MR</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>PG</given-names></name><name name-style="western"><surname>Geddes</surname><given-names>JW</given-names></name></person-group>             <year>2006</year>             <article-title>Synaptic mitochondria are more susceptible to Ca2+overload than nonsynaptic mitochondria.</article-title>             <source>J Biol Chem</source>             <volume>281</volume>             <fpage>11658</fpage>             <lpage>11668</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Cha1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>GH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>102</volume>             <fpage>10345</fpage>             <lpage>10350</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Yang2">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gehrke</surname><given-names>S</given-names></name><name name-style="western"><surname>Haque</surname><given-names>ME</given-names></name><name name-style="western"><surname>Imai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kosek</surname><given-names>J</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>102</volume>             <fpage>13670</fpage>             <lpage>13675</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Timmons1">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Timmons</surname><given-names>S</given-names></name><name name-style="western"><surname>Coakley</surname><given-names>MF</given-names></name><name name-style="western"><surname>Moloney</surname><given-names>AM</given-names></name><name name-style="western"><surname>O'Neill</surname><given-names>C</given-names></name></person-group>             <year>2009</year>             <article-title>Akt signal transduction dysfunction in Parkinson's disease.</article-title>             <source>Neurosci Lett</source>             <volume>467</volume>             <fpage>30</fpage>             <lpage>35</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Mogi1">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mogi</surname><given-names>M</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>T</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nagatsu</surname><given-names>T</given-names></name></person-group>             <year>2007</year>             <article-title>p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.</article-title>             <source>Neurosci Lett</source>             <volume>414</volume>             <fpage>94</fpage>             <lpage>97</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Chen1">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>BP</given-names></name><name name-style="western"><surname>Wolfgang</surname><given-names>CD</given-names></name><name name-style="western"><surname>Hai</surname><given-names>T</given-names></name></person-group>             <year>1996</year>             <article-title>Analysis of ATF3, a transcription factor induced by physiological stresses and modulated by gadd153/Chop10.</article-title>             <source>Mol Cell Biol</source>             <volume>16</volume>             <fpage>1157</fpage>             <lpage>1168</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Lu1">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Hai</surname><given-names>T</given-names></name></person-group>             <year>2007</year>             <article-title>The regulation of ATF3 gene expression by mitogen-activated protein kinases.</article-title>             <source>Biochem J</source>             <volume>401</volume>             <fpage>559</fpage>             <lpage>567</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Dragunow1">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dragunow</surname><given-names>M</given-names></name><name name-style="western"><surname>Butterworth</surname><given-names>N</given-names></name><name name-style="western"><surname>Waldvogel</surname><given-names>H</given-names></name><name name-style="western"><surname>Faull</surname><given-names>RL</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>LF</given-names></name></person-group>             <year>1995</year>             <article-title>Prolonged expression of Fos-related antigens, Jun B and TrkB in dopamine-denervated striatal neurons.</article-title>             <source>Brain Res Mol Brain Res</source>             <volume>30</volume>             <fpage>393</fpage>             <lpage>396</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Joh1">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Joh</surname><given-names>TH</given-names></name><name name-style="western"><surname>Weiser</surname><given-names>M</given-names></name></person-group>             <year>1993</year>             <article-title>Early and late molecular events occurring following neuronal degeneration in the dopamine system.</article-title>             <source>Adv Neurol</source>             <volume>60</volume>             <fpage>316</fpage>             <lpage>320</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Badiani1">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Badiani</surname><given-names>A</given-names></name><name name-style="western"><surname>Oates</surname><given-names>MM</given-names></name><name name-style="western"><surname>Day</surname><given-names>HE</given-names></name><name name-style="western"><surname>Watson</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Akil</surname><given-names>H</given-names></name><etal/></person-group>             <year>1998</year>             <article-title>Amphetamine-induced behavior, dopamine release, and c-fos mRNA expression: modulation by environmental novelty.</article-title>             <source>J Neurosci</source>             <volume>18</volume>             <fpage>10579</fpage>             <lpage>10593</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Svenningsson1">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Svenningsson</surname><given-names>P</given-names></name><name name-style="western"><surname>Gunne</surname><given-names>L</given-names></name><name name-style="western"><surname>Andren</surname><given-names>PE</given-names></name></person-group>             <year>2000</year>             <article-title>L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset.</article-title>             <source>Neuroscience</source>             <volume>99</volume>             <fpage>457</fpage>             <lpage>468</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Robertson1">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Robertson</surname><given-names>GS</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>SR</given-names></name><name name-style="western"><surname>Fibiger</surname><given-names>HC</given-names></name></person-group>             <year>1992</year>             <article-title>D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons.</article-title>             <source>Neuroscience</source>             <volume>49</volume>             <fpage>285</fpage>             <lpage>296</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Beauvais1">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Beauvais</surname><given-names>G</given-names></name><name name-style="western"><surname>Jayanthi</surname><given-names>S</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>MT</given-names></name><name name-style="western"><surname>Ladenheim</surname><given-names>B</given-names></name><name name-style="western"><surname>Cadet</surname><given-names>JL</given-names></name></person-group>             <year>2010</year>             <article-title>Differential effects of methamphetamine and SCH23390 on the expression of members of IEG families of transcription factors in the rat striatum.</article-title>             <source>Brain Res</source>             <volume>1318</volume>             <fpage>1</fpage>             <lpage>10</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-DeSteno1">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>De Steno</surname><given-names>DA</given-names></name><name name-style="western"><surname>Schmauss</surname><given-names>C</given-names></name></person-group>             <year>2009</year>             <article-title>A role for dopamine D2 receptors in reversal learning.</article-title>             <source>Neuroscience</source>             <volume>162</volume>             <fpage>118</fpage>             <lpage>127</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Kim2">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>KH</given-names></name><name name-style="western"><surname>Min</surname><given-names>YK</given-names></name><name name-style="western"><surname>Baik</surname><given-names>JH</given-names></name><name name-style="western"><surname>Lau</surname><given-names>LF</given-names></name><name name-style="western"><surname>Chaqour</surname><given-names>B</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Expression of angiogenic factor Cyr61 during neuronal cell death via the activation of c-Jun N-terminal kinase and serum response factor.</article-title>             <source>J Biol Chem</source>             <volume>278</volume>             <fpage>13847</fpage>             <lpage>13854</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Lee1">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>HY</given-names></name><name name-style="western"><surname>Chung</surname><given-names>JW</given-names></name><name name-style="western"><surname>Youn</surname><given-names>SW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name><name name-style="western"><surname>Park</surname><given-names>KW</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Forkhead transcription factor FOXO3a is a negative regulator of angiogenic immediate early gene CYR61, leading to inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia.</article-title>             <source>Circ Res</source>             <volume>100</volume>             <fpage>372</fpage>             <lpage>380</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Mei1">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W</given-names></name><name name-style="western"><surname>Mak</surname><given-names>TW</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>FOXO3a-dependent regulation of Pink1 (Park6) mediates survival signaling in response to cytokine deprivation.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>106</volume>             <fpage>5153</fpage>             <lpage>5158</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Falk1">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Falk</surname><given-names>A</given-names></name><name name-style="western"><surname>Frisen</surname><given-names>J</given-names></name></person-group>             <year>2002</year>             <article-title>Amphiregulin is a mitogen for adult neural stem cells.</article-title>             <source>J Neurosci Res</source>             <volume>69</volume>             <fpage>757</fpage>             <lpage>762</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Nilsson1">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nilsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Kanje</surname><given-names>M</given-names></name></person-group>             <year>2005</year>             <article-title>Amphiregulin acts as an autocrine survival factor for adult sensory neurons.</article-title>             <source>Neuroreport</source>             <volume>16</volume>             <fpage>213</fpage>             <lpage>218</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Sun1">
        <label>44</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>SC</given-names></name><name name-style="western"><surname>Ganchi</surname><given-names>PA</given-names></name><name name-style="western"><surname>Ballard</surname><given-names>DW</given-names></name><name name-style="western"><surname>Greene</surname><given-names>WC</given-names></name></person-group>             <year>1993</year>             <article-title>NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway.</article-title>             <source>Science</source>             <volume>259</volume>             <fpage>1912</fpage>             <lpage>1915</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Zhou1">
        <label>45</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>A</given-names></name><name name-style="western"><surname>Scoggin</surname><given-names>S</given-names></name><name name-style="western"><surname>Gaynor</surname><given-names>RB</given-names></name><name name-style="western"><surname>Williams</surname><given-names>NS</given-names></name></person-group>             <year>2003</year>             <article-title>Identification of NF-kappa B-regulated genes induced by TNFalpha utilizing expression profiling and RNA interference.</article-title>             <source>Oncogene</source>             <volume>22</volume>             <fpage>2054</fpage>             <lpage>2064</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Wang1">
        <label>46</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cao</surname><given-names>N</given-names></name><name name-style="western"><surname>Nantajit</surname><given-names>D</given-names></name><name name-style="western"><surname>Fan</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Mitogen-activated protein kinase phosphatase-1 represses c-Jun NH2-terminal kinase-mediated apoptosis via NF-kappaB regulation.</article-title>             <source>J Biol Chem</source>             <volume>283</volume>             <fpage>21011</fpage>             <lpage>21023</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Lang1">
        <label>47</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>R</given-names></name><name name-style="western"><surname>Hammer</surname><given-names>M</given-names></name><name name-style="western"><surname>Mages</surname><given-names>J</given-names></name></person-group>             <year>2006</year>             <article-title>DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response.</article-title>             <source>J Immunol</source>             <volume>177</volume>             <fpage>7497</fpage>             <lpage>7504</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Liu1">
        <label>48</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>EG</given-names></name><name name-style="western"><surname>Nelin</surname><given-names>LD</given-names></name></person-group>             <year>2007</year>             <article-title>MAPK phosphatases—regulating the immune response.</article-title>             <source>Nat Rev Immunol</source>             <volume>7</volume>             <fpage>202</fpage>             <lpage>212</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Chen2">
        <label>49</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Chou</surname><given-names>CW</given-names></name><name name-style="western"><surname>Chang</surname><given-names>YF</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CC</given-names></name></person-group>             <year>2008</year>             <article-title>Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation.</article-title>             <source>J Immunol</source>             <volume>180</volume>             <fpage>8030</fpage>             <lpage>8039</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Tang1">
        <label>50</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner.</article-title>             <source>Cell Res</source>             <volume>19</volume>             <fpage>758</fpage>             <lpage>767</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Gerritsen1">
        <label>51</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gerritsen</surname><given-names>ME</given-names></name><name name-style="western"><surname>Williams</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Neish</surname><given-names>AS</given-names></name><name name-style="western"><surname>Moore</surname><given-names>S</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group>             <year>1997</year>             <article-title>CREB-binding protein/p300 are transcriptional coactivators of p65.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>94</volume>             <fpage>2927</fpage>             <lpage>2932</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Deng1">
        <label>52</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>WG</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>KK</given-names></name></person-group>             <year>2004</year>             <article-title>Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators.</article-title>             <source>Blood</source>             <volume>103</volume>             <fpage>2135</fpage>             <lpage>2142</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Kiernan1">
        <label>53</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kiernan</surname><given-names>R</given-names></name><name name-style="western"><surname>Bres</surname><given-names>V</given-names></name><name name-style="western"><surname>Ng</surname><given-names>RW</given-names></name><name name-style="western"><surname>Coudart</surname><given-names>MP</given-names></name><name name-style="western"><surname>El Messaoudi</surname><given-names>S</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65.</article-title>             <source>J Biol Chem</source>             <volume>278</volume>             <fpage>2758</fpage>             <lpage>2766</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Wilson1">
        <label>54</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>NS</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>V</given-names></name><name name-style="western"><surname>Ashkenazi</surname><given-names>A</given-names></name></person-group>             <year>2009</year>             <article-title>Death receptor signal transducers: nodes of coordination in immune signaling networks.</article-title>             <source>Nat Immunol</source>             <volume>10</volume>             <fpage>348</fpage>             <lpage>355</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Silke1">
        <label>55</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Silke</surname><given-names>J</given-names></name><name name-style="western"><surname>Brink</surname><given-names>R</given-names></name></person-group>             <year>2010</year>             <article-title>Regulation of TNFRSF and innate immune signalling complexes by TRAFs and cIAPs.</article-title>             <source>Cell Death Differ</source>             <volume>17</volume>             <fpage>35</fpage>             <lpage>45</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Karin1">
        <label>56</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Karin</surname><given-names>M</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>E</given-names></name></person-group>             <year>2009</year>             <article-title>TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes.</article-title>             <source>Immunol Rev</source>             <volume>228</volume>             <fpage>225</fpage>             <lpage>240</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Nagao1">
        <label>57</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nagao</surname><given-names>M</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>H</given-names></name></person-group>             <year>2009</year>             <article-title>Glycogen synthase kinase-3beta is associated with Parkinson's disease.</article-title>             <source>Neurosci Lett</source>             <volume>449</volume>             <fpage>103</fpage>             <lpage>107</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-GarciaGorostiaga1">
        <label>58</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Garcia-Gorostiaga</surname><given-names>I</given-names></name><name name-style="western"><surname>Sanchez-Juan</surname><given-names>P</given-names></name><name name-style="western"><surname>Mateo</surname><given-names>I</given-names></name><name name-style="western"><surname>Rodriguez-Rodriguez</surname><given-names>E</given-names></name><name name-style="western"><surname>Sanchez-Quintana</surname><given-names>C</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Glycogen synthase kinase-3 beta and tau genes interact in Parkinson's and Alzheimer's diseases.</article-title>             <source>Ann Neurol</source>             <volume>65</volume>             <fpage>759</fpage>             <lpage>761; author reply 761-752</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Avraham1">
        <label>59</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Avraham</surname><given-names>E</given-names></name><name name-style="western"><surname>Szargel</surname><given-names>R</given-names></name><name name-style="western"><surname>Eyal</surname><given-names>A</given-names></name><name name-style="western"><surname>Rott</surname><given-names>R</given-names></name><name name-style="western"><surname>Engelender</surname><given-names>S</given-names></name></person-group>             <year>2005</year>             <article-title>Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: implications for proteasomal function and Lewy body formation.</article-title>             <source>J Biol Chem</source>             <volume>280</volume>             <fpage>42877</fpage>             <lpage>42886</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Chen3">
        <label>60</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Bower</surname><given-names>KA</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S</given-names></name><name name-style="western"><surname>Thiele</surname><given-names>CJ</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death.</article-title>             <source>FASEB J</source>             <volume>18</volume>             <fpage>1162</fpage>             <lpage>1164</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Vallabhapurapu1">
        <label>61</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Vallabhapurapu</surname><given-names>S</given-names></name><name name-style="western"><surname>Karin</surname><given-names>M</given-names></name></person-group>             <year>2009</year>             <article-title>Regulation and function of NF-kappaB transcription factors in the immune system.</article-title>             <source>Annu Rev Immunol</source>             <volume>27</volume>             <fpage>693</fpage>             <lpage>733</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Verstrepen1">
        <label>62</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Verstrepen</surname><given-names>L</given-names></name><name name-style="western"><surname>Bekaert</surname><given-names>T</given-names></name><name name-style="western"><surname>Chau</surname><given-names>TL</given-names></name><name name-style="western"><surname>Tavernier</surname><given-names>J</given-names></name><name name-style="western"><surname>Chariot</surname><given-names>A</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme.</article-title>             <source>Cell Mol Life Sci</source>             <volume>65</volume>             <fpage>2964</fpage>             <lpage>2978</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Rivest1">
        <label>63</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Rivest</surname><given-names>S</given-names></name></person-group>             <year>2009</year>             <article-title>Regulation of innate immune responses in the brain.</article-title>             <source>Nat Rev Immunol</source>             <volume>9</volume>             <fpage>429</fpage>             <lpage>439</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Gayle1">
        <label>64</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gayle</surname><given-names>DA</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tong</surname><given-names>C</given-names></name><name name-style="western"><surname>Landers</surname><given-names>T</given-names></name><name name-style="western"><surname>Lipton</surname><given-names>JW</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide.</article-title>             <source>Brain Res Dev Brain Res</source>             <volume>133</volume>             <fpage>27</fpage>             <lpage>35</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Ferrari1">
        <label>65</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ferrari</surname><given-names>CC</given-names></name><name name-style="western"><surname>Pott Godoy</surname><given-names>MC</given-names></name><name name-style="western"><surname>Tarelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Chertoff</surname><given-names>M</given-names></name><name name-style="western"><surname>Depino</surname><given-names>AM</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra.</article-title>             <source>Neurobiol Dis</source>             <volume>24</volume>             <fpage>183</fpage>             <lpage>193</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-PottGodoy1">
        <label>66</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pott Godoy</surname><given-names>MC</given-names></name><name name-style="western"><surname>Tarelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>CC</given-names></name><name name-style="western"><surname>Sarchi</surname><given-names>MI</given-names></name><name name-style="western"><surname>Pitossi</surname><given-names>FJ</given-names></name></person-group>             <year>2008</year>             <article-title>Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease.</article-title>             <source>Brain</source>             <volume>131</volume>             <fpage>1880</fpage>             <lpage>1894</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Sriram1">
        <label>67</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sriram</surname><given-names>K</given-names></name><name name-style="western"><surname>Matheson</surname><given-names>JM</given-names></name><name name-style="western"><surname>Benkovic</surname><given-names>SA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>DB</given-names></name><name name-style="western"><surname>Luster</surname><given-names>MI</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.</article-title>             <source>FASEB J</source>             <volume>16</volume>             <fpage>1474</fpage>             <lpage>1476</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-McCoy1">
        <label>68</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>McCoy</surname><given-names>MK</given-names></name><name name-style="western"><surname>Ruhn</surname><given-names>KA</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>TN</given-names></name><name name-style="western"><surname>McAlpine</surname><given-names>FE</given-names></name><name name-style="western"><surname>Blesch</surname><given-names>A</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats.</article-title>             <source>Mol Ther</source>             <volume>16</volume>             <fpage>1572</fpage>             <lpage>1579</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Chan1">
        <label>69</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>CS</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>JN</given-names></name><name name-style="western"><surname>Ilijic</surname><given-names>E</given-names></name><name name-style="western"><surname>Mercer</surname><given-names>JN</given-names></name><name name-style="western"><surname>Rick</surname><given-names>C</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>‘Rejuvenation’ protects neurons in mouse models of Parkinson's disease.</article-title>             <source>Nature</source>             <volume>447</volume>             <fpage>1081</fpage>             <lpage>1086</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Surmeier1">
        <label>70</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Surmeier</surname><given-names>DJ</given-names></name></person-group>             <year>2007</year>             <article-title>Calcium, ageing, and neuronal vulnerability in Parkinson's disease.</article-title>             <source>Lancet Neurol</source>             <volume>6</volume>             <fpage>933</fpage>             <lpage>938</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Svenningsson2">
        <label>71</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Svenningsson</surname><given-names>P</given-names></name><name name-style="western"><surname>Nishi</surname><given-names>A</given-names></name><name name-style="western"><surname>Fisone</surname><given-names>G</given-names></name><name name-style="western"><surname>Girault</surname><given-names>JA</given-names></name><name name-style="western"><surname>Nairn</surname><given-names>AC</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>DARPP-32: an integrator of neurotransmission.</article-title>             <source>Annu Rev Pharmacol Toxicol</source>             <volume>44</volume>             <fpage>269</fpage>             <lpage>296</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Levy1">
        <label>72</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>OA</given-names></name><name name-style="western"><surname>Malagelada</surname><given-names>C</given-names></name><name name-style="western"><surname>Greene</surname><given-names>LA</given-names></name></person-group>             <year>2009</year>             <article-title>Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps.</article-title>             <source>Apoptosis</source>             <volume>14</volume>             <fpage>478</fpage>             <lpage>500</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Ferrer1">
        <label>73</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ferrer</surname><given-names>I</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>R</given-names></name><name name-style="western"><surname>Carmona</surname><given-names>M</given-names></name><name name-style="western"><surname>Puig</surname><given-names>B</given-names></name><name name-style="western"><surname>Barrachina</surname><given-names>M</given-names></name><etal/></person-group>             <year>2001</year>             <article-title>Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies.</article-title>             <source>J Neural Transm</source>             <volume>108</volume>             <fpage>1383</fpage>             <lpage>1396</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Hunot1">
        <label>74</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hunot</surname><given-names>S</given-names></name><name name-style="western"><surname>Vila</surname><given-names>M</given-names></name><name name-style="western"><surname>Teismann</surname><given-names>P</given-names></name><name name-style="western"><surname>Davis</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>EC</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>101</volume>             <fpage>665</fpage>             <lpage>670</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Brecht1">
        <label>75</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Brecht</surname><given-names>S</given-names></name><name name-style="western"><surname>Kirchhof</surname><given-names>R</given-names></name><name name-style="western"><surname>Chromik</surname><given-names>A</given-names></name><name name-style="western"><surname>Willesen</surname><given-names>M</given-names></name><name name-style="western"><surname>Nicolaus</surname><given-names>T</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Specific pathophysiological functions of JNK isoforms in the brain.</article-title>             <source>Eur J Neurosci</source>             <volume>21</volume>             <fpage>363</fpage>             <lpage>377</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Ziviani1">
        <label>76</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ziviani</surname><given-names>E</given-names></name><name name-style="western"><surname>Tao</surname><given-names>RN</given-names></name><name name-style="western"><surname>Whitworth</surname><given-names>AJ</given-names></name></person-group>             <year>2010</year>             <article-title>Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>107</volume>             <fpage>5018</fpage>             <lpage>5023</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Sossi1">
        <label>77</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sossi</surname><given-names>V</given-names></name><name name-style="western"><surname>de La Fuente-Fernandez</surname><given-names>R</given-names></name><name name-style="western"><surname>Holden</surname><given-names>JE</given-names></name><name name-style="western"><surname>Doudet</surname><given-names>DJ</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>J</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data.</article-title>             <source>J Cereb Blood Flow Metab</source>             <volume>22</volume>             <fpage>232</fpage>             <lpage>239</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Spina1">
        <label>78</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Spina</surname><given-names>MB</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>G</given-names></name></person-group>             <year>1989</year>             <article-title>Dopamine turnover and glutathione oxidation: implications for Parkinson disease.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>86</volume>             <fpage>1398</fpage>             <lpage>1400</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Winter1">
        <label>79</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Winter</surname><given-names>C</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>J</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>M</given-names></name><name name-style="western"><surname>Herdegen</surname><given-names>T</given-names></name></person-group>             <year>1998</year>             <article-title>MAP kinase phosphatase 1 is expressed and enhanced by FK506 in surviving mamillary, but not degenerating nigral neurons following axotomy.</article-title>             <source>Brain Res</source>             <volume>801</volume>             <fpage>198</fpage>             <lpage>205</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Salojin1">
        <label>80</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Salojin</surname><given-names>KV</given-names></name><name name-style="western"><surname>Owusu</surname><given-names>IB</given-names></name><name name-style="western"><surname>Millerchip</surname><given-names>KA</given-names></name><name name-style="western"><surname>Potter</surname><given-names>M</given-names></name><name name-style="western"><surname>Platt</surname><given-names>KA</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Essential role of MAPK phosphatase-1 in the negative control of innate immune responses.</article-title>             <source>J Immunol</source>             <volume>176</volume>             <fpage>1899</fpage>             <lpage>1907</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Chi1">
        <label>81</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chi</surname><given-names>H</given-names></name><name name-style="western"><surname>Barry</surname><given-names>SP</given-names></name><name name-style="western"><surname>Roth</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Jones</surname><given-names>EA</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>103</volume>             <fpage>2274</fpage>             <lpage>2279</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Hammer1">
        <label>82</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hammer</surname><given-names>M</given-names></name><name name-style="western"><surname>Mages</surname><given-names>J</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>H</given-names></name><name name-style="western"><surname>Servatius</surname><given-names>A</given-names></name><name name-style="western"><surname>Howells</surname><given-names>N</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock.</article-title>             <source>J Exp Med</source>             <volume>203</volume>             <fpage>15</fpage>             <lpage>20</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Gilchrist1">
        <label>83</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gilchrist</surname><given-names>M</given-names></name><name name-style="western"><surname>Thorsson</surname><given-names>V</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Rust</surname><given-names>AG</given-names></name><name name-style="western"><surname>Korb</surname><given-names>M</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4.</article-title>             <source>Nature</source>             <volume>441</volume>             <fpage>173</fpage>             <lpage>178</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Whitmore1">
        <label>84</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Whitmore</surname><given-names>MM</given-names></name><name name-style="western"><surname>Iparraguirre</surname><given-names>A</given-names></name><name name-style="western"><surname>Kubelka</surname><given-names>L</given-names></name><name name-style="western"><surname>Weninger</surname><given-names>W</given-names></name><name name-style="western"><surname>Hai</surname><given-names>T</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Negative regulation of TLR-signaling pathways by activating transcription factor-3.</article-title>             <source>J Immunol</source>             <volume>179</volume>             <fpage>3622</fpage>             <lpage>3630</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Diehl1">
        <label>85</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Diehl</surname><given-names>GE</given-names></name><name name-style="western"><surname>Yue</surname><given-names>HH</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>K</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>AA</given-names></name><name name-style="western"><surname>Ho</surname><given-names>M</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>TRAIL-R as a negative regulator of innate immune cell responses.</article-title>             <source>Immunity</source>             <volume>21</volume>             <fpage>877</fpage>             <lpage>889</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Finnberg1">
        <label>86</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Finnberg</surname><given-names>N</given-names></name><name name-style="western"><surname>Klein-Szanto</surname><given-names>AJ</given-names></name><name name-style="western"><surname>El-Deiry</surname><given-names>WS</given-names></name></person-group>             <year>2008</year>             <article-title>TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.</article-title>             <source>J Clin Invest</source>             <volume>118</volume>             <fpage>111</fpage>             <lpage>123</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Sriram2">
        <label>87</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sriram</surname><given-names>K</given-names></name><name name-style="western"><surname>Matheson</surname><given-names>JM</given-names></name><name name-style="western"><surname>Benkovic</surname><given-names>SA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>DB</given-names></name><name name-style="western"><surname>Luster</surname><given-names>MI</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.</article-title>             <source>FASEB J</source>             <volume>20</volume>             <fpage>670</fpage>             <lpage>682</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Hoeflich1">
        <label>88</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hoeflich</surname><given-names>KP</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name><name name-style="western"><surname>Rubie</surname><given-names>EA</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>MS</given-names></name><name name-style="western"><surname>Jin</surname><given-names>O</given-names></name><etal/></person-group>             <year>2000</year>             <article-title>Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.</article-title>             <source>Nature</source>             <volume>406</volume>             <fpage>86</fpage>             <lpage>90</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Graham1">
        <label>89</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>JR</given-names></name><name name-style="western"><surname>Tullai</surname><given-names>JW</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>GM</given-names></name></person-group>             <year>2010</year>             <article-title>GSK-3 represses growth factor-inducible genes by inhibiting NF-kappaB in quiescent cells.</article-title>             <source>J Biol Chem</source>             <volume>285</volume>             <fpage>4472</fpage>             <lpage>4480</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Steinbrecher1">
        <label>90</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Steinbrecher</surname><given-names>KA</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>W</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Cogswell</surname><given-names>PC</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>AS</given-names></name></person-group>             <year>2005</year>             <article-title>Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription.</article-title>             <source>Mol Cell Biol</source>             <volume>25</volume>             <fpage>8444</fpage>             <lpage>8455</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Takada1">
        <label>91</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Takada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X</given-names></name><name name-style="western"><surname>Jamaluddin</surname><given-names>MS</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>DD</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group>             <year>2004</year>             <article-title>Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor.</article-title>             <source>J Biol Chem</source>             <volume>279</volume>             <fpage>39541</fpage>             <lpage>39554</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Martin1">
        <label>92</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>M</given-names></name><name name-style="western"><surname>Rehani</surname><given-names>K</given-names></name><name name-style="western"><surname>Jope</surname><given-names>RS</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>SM</given-names></name></person-group>             <year>2005</year>             <article-title>Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3.</article-title>             <source>Nat Immunol</source>             <volume>6</volume>             <fpage>777</fpage>             <lpage>784</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Beurel1">
        <label>93</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Beurel</surname><given-names>E</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>SM</given-names></name><name name-style="western"><surname>Jope</surname><given-names>RS</given-names></name></person-group>             <article-title>Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3).</article-title>             <source>Trends Immunol</source>             <volume>31</volume>             <fpage>24</fpage>             <lpage>31</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Vines1">
        <label>94</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Vines</surname><given-names>A</given-names></name><name name-style="western"><surname>Cahoon</surname><given-names>S</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>I</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>U</given-names></name><name name-style="western"><surname>Pillarisetti</surname><given-names>S</given-names></name></person-group>             <year>2006</year>             <article-title>Novel anti-inflammatory role for glycogen synthase kinase-3beta in the inhibition of tumor necrosis factor-alpha- and interleukin-1beta-induced inflammatory gene expression.</article-title>             <source>J Biol Chem</source>             <volume>281</volume>             <fpage>16985</fpage>             <lpage>16990</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Martinon1">
        <label>95</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Martinon</surname><given-names>F</given-names></name></person-group>             <year>2010</year>             <article-title>Signaling by ROS drives inflammasome activation.</article-title>             <source>Eur J Immunol</source>             <volume>40</volume>             <fpage>616</fpage>             <lpage>619</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Gill1">
        <label>96</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gill</surname><given-names>R</given-names></name><name name-style="western"><surname>Tsung</surname><given-names>A</given-names></name><name name-style="western"><surname>Billiar</surname><given-names>T</given-names></name></person-group>             <year>2010</year>             <article-title>Linking oxidative stress to inflammation: Toll-like receptors.</article-title>             <source>Free Radic Biol Med</source>             <volume>48</volume>             <fpage>1121</fpage>             <lpage>1132</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Tansey1">
        <label>97</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Tansey</surname><given-names>MG</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>MS</given-names></name></person-group>             <year>2010</year>             <article-title>Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.</article-title>             <source>Neurobiol Dis</source>             <volume>37</volume>             <fpage>510</fpage>             <lpage>518</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Liu2">
        <label>98</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Choi</surname><given-names>DY</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>RL</given-names></name><name name-style="western"><surname>Pandya</surname><given-names>JD</given-names></name><name name-style="western"><surname>Cass</surname><given-names>WA</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats.</article-title>             <source>J Neurochem</source>             <volume>112</volume>             <fpage>773</fpage>             <lpage>783</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Doucet1">
        <label>99</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Doucet</surname><given-names>JP</given-names></name><name name-style="western"><surname>Nakabeppu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bedard</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Hope</surname><given-names>BT</given-names></name><name name-style="western"><surname>Nestler</surname><given-names>EJ</given-names></name><etal/></person-group>             <year>1996</year>             <article-title>Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.</article-title>             <source>Eur J Neurosci</source>             <volume>8</volume>             <fpage>365</fpage>             <lpage>381</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Dragunow2">
        <label>100</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dragunow</surname><given-names>M</given-names></name><name name-style="western"><surname>Leah</surname><given-names>JD</given-names></name><name name-style="western"><surname>Faull</surname><given-names>RL</given-names></name></person-group>             <year>1991</year>             <article-title>Prolonged and selective induction of Fos-related antigen(s) in striatal neurons after 6-hydroxydopamine lesions of the rat substantia nigra pars compacta.</article-title>             <source>Brain Res Mol Brain Res</source>             <volume>10</volume>             <fpage>355</fpage>             <lpage>358</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Winter2">
        <label>101</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Winter</surname><given-names>C</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>C</given-names></name><name name-style="western"><surname>Martin-Villalba</surname><given-names>A</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>M</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>J</given-names></name></person-group>             <year>2002</year>             <article-title>JunB and Bcl-2 overexpression results in protection against cell death of nigral neurons following axotomy.</article-title>             <source>Brain Res Mol Brain Res</source>             <volume>104</volume>             <fpage>194</fpage>             <lpage>202</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Seijffers1">
        <label>102</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Seijffers</surname><given-names>R</given-names></name><name name-style="western"><surname>Mills</surname><given-names>CD</given-names></name><name name-style="western"><surname>Woolf</surname><given-names>CJ</given-names></name></person-group>             <year>2007</year>             <article-title>ATF3 increases the intrinsic growth state of DRG neurons to enhance peripheral nerve regeneration.</article-title>             <source>J Neurosci</source>             <volume>27</volume>             <fpage>7911</fpage>             <lpage>7920</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Pearson1">
        <label>103</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pearson</surname><given-names>AG</given-names></name><name name-style="western"><surname>Gray</surname><given-names>CW</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>JF</given-names></name><name name-style="western"><surname>Greenwood</surname><given-names>JM</given-names></name><name name-style="western"><surname>During</surname><given-names>MJ</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>ATF3 enhances c-Jun-mediated neurite sprouting.</article-title>             <source>Brain Res Mol Brain Res</source>             <volume>120</volume>             <fpage>38</fpage>             <lpage>45</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Saito1">
        <label>104</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>H</given-names></name><name name-style="western"><surname>Dahlin</surname><given-names>LB</given-names></name></person-group>             <year>2008</year>             <article-title>Expression of ATF3 and axonal outgrowth are impaired after delayed nerve repair.</article-title>             <source>BMC Neurosci</source>             <volume>9</volume>             <fpage>88</fpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Campbell1">
        <label>105</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>G</given-names></name><name name-style="western"><surname>Hutchins</surname><given-names>K</given-names></name><name name-style="western"><surname>Winterbottom</surname><given-names>J</given-names></name><name name-style="western"><surname>Grenningloh</surname><given-names>G</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>AR</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Upregulation of activating transcription factor 3 (ATF3) by intrinsic CNS neurons regenerating axons into peripheral nerve grafts.</article-title>             <source>Exp Neurol</source>             <volume>192</volume>             <fpage>340</fpage>             <lpage>347</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Francis1">
        <label>106</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Francis</surname><given-names>JS</given-names></name><name name-style="western"><surname>Dragunow</surname><given-names>M</given-names></name><name name-style="western"><surname>During</surname><given-names>MJ</given-names></name></person-group>             <year>2004</year>             <article-title>Over expression of ATF-3 protects rat hippocampal neurons from in vivo injection of kainic acid.</article-title>             <source>Brain Res Mol Brain Res</source>             <volume>124</volume>             <fpage>199</fpage>             <lpage>203</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Liang1">
        <label>107</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ratovitski</surname><given-names>T</given-names></name><name name-style="western"><surname>Jie</surname><given-names>C</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>ATF3 plays a protective role against toxicity by N-terminal fragment of mutant huntingtin in stable PC12 cell line.</article-title>             <source>Brain Res</source>             <volume>1286</volume>             <fpage>221</fpage>             <lpage>229</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Vlug1">
        <label>108</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Vlug</surname><given-names>AS</given-names></name><name name-style="western"><surname>Teuling</surname><given-names>E</given-names></name><name name-style="western"><surname>Haasdijk</surname><given-names>ED</given-names></name><name name-style="western"><surname>French</surname><given-names>P</given-names></name><name name-style="western"><surname>Hoogenraad</surname><given-names>CC</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>ATF3 expression precedes death of spinal motoneurons in amyotrophic lateral sclerosis-SOD1 transgenic mice and correlates with c-Jun phosphorylation, CHOP expression, somato-dendritic ubiquitination and Golgi fragmentation.</article-title>             <source>Eur J Neurosci</source>             <volume>22</volume>             <fpage>1881</fpage>             <lpage>1894</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Song1">
        <label>109</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>DY</given-names></name><name name-style="western"><surname>Yang</surname><given-names>YC</given-names></name><name name-style="western"><surname>Shin</surname><given-names>DH</given-names></name><name name-style="western"><surname>Sugama</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YS</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Axotomy-induced dopaminergic neurodegeneration is accompanied with c-Jun phosphorylation and activation transcription factor 3 expression.</article-title>             <source>Exp Neurol</source>             <volume>209</volume>             <fpage>268</fpage>             <lpage>278</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Nakagomi1">
        <label>110</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nakagomi</surname><given-names>S</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Namikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Kiryu-Seo</surname><given-names>S</given-names></name><name name-style="western"><surname>Kiyama</surname><given-names>H</given-names></name></person-group>             <year>2003</year>             <article-title>Expression of the activating transcription factor 3 prevents c-Jun N-terminal kinase-induced neuronal death by promoting heat shock protein 27 expression and Akt activation.</article-title>             <source>J Neurosci</source>             <volume>23</volume>             <fpage>5187</fpage>             <lpage>5196</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Mogi2">
        <label>111</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mogi</surname><given-names>M</given-names></name><name name-style="western"><surname>Harada</surname><given-names>M</given-names></name><name name-style="western"><surname>Narabayashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Inagaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Minami</surname><given-names>M</given-names></name><etal/></person-group>             <year>1996</year>             <article-title>Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease.</article-title>             <source>Neurosci Lett</source>             <volume>211</volume>             <fpage>13</fpage>             <lpage>16</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Mogi3">
        <label>112</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mogi</surname><given-names>M</given-names></name><name name-style="western"><surname>Harada</surname><given-names>M</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>T</given-names></name><name name-style="western"><surname>Riederer</surname><given-names>P</given-names></name><name name-style="western"><surname>Inagaki</surname><given-names>H</given-names></name><etal/></person-group>             <year>1994</year>             <article-title>Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients.</article-title>             <source>Neurosci Lett</source>             <volume>180</volume>             <fpage>147</fpage>             <lpage>150</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Mogi4">
        <label>113</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mogi</surname><given-names>M</given-names></name><name name-style="western"><surname>Harada</surname><given-names>M</given-names></name><name name-style="western"><surname>Riederer</surname><given-names>P</given-names></name><name name-style="western"><surname>Narabayashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>K</given-names></name><etal/></person-group>             <year>1994</year>             <article-title>Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients.</article-title>             <source>Neurosci Lett</source>             <volume>165</volume>             <fpage>208</fpage>             <lpage>210</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Brodacki1">
        <label>114</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Brodacki</surname><given-names>B</given-names></name><name name-style="western"><surname>Staszewski</surname><given-names>J</given-names></name><name name-style="western"><surname>Toczylowska</surname><given-names>B</given-names></name><name name-style="western"><surname>Kozlowska</surname><given-names>E</given-names></name><name name-style="western"><surname>Drela</surname><given-names>N</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism.</article-title>             <source>Neurosci Lett</source>             <volume>441</volume>             <fpage>158</fpage>             <lpage>162</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Rentzos1">
        <label>115</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Rentzos</surname><given-names>M</given-names></name><name name-style="western"><surname>Nikolaou</surname><given-names>C</given-names></name><name name-style="western"><surname>Andreadou</surname><given-names>E</given-names></name><name name-style="western"><surname>Paraskevas</surname><given-names>GP</given-names></name><name name-style="western"><surname>Rombos</surname><given-names>A</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Circulating interleukin-10 and interleukin-12 in Parkinson's disease.</article-title>             <source>Acta Neurol Scand</source>             <volume>119</volume>             <fpage>332</fpage>             <lpage>337</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Johnston1">
        <label>116</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>LC</given-names></name><name name-style="western"><surname>Su</surname><given-names>X</given-names></name><name name-style="western"><surname>Maguire-Zeiss</surname><given-names>K</given-names></name><name name-style="western"><surname>Horovitz</surname><given-names>K</given-names></name><name name-style="western"><surname>Ankoudinova</surname><given-names>I</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease.</article-title>             <source>Mol Ther</source>             <volume>16</volume>             <fpage>1392</fpage>             <lpage>1399</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Cadet1">
        <label>117</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cadet</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><name name-style="western"><surname>Mantione</surname><given-names>K</given-names></name><name name-style="western"><surname>Rymer</surname><given-names>M</given-names></name><name name-style="western"><surname>Dardik</surname><given-names>I</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Cyclic exercise induces anti-inflammatory signal molecule increases in the plasma of Parkinson's patients.</article-title>             <source>Int J Mol Med</source>             <volume>12</volume>             <fpage>485</fpage>             <lpage>492</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Wu1">
        <label>118</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>DC</given-names></name><name name-style="western"><surname>Jackson-Lewis</surname><given-names>V</given-names></name><name name-style="western"><surname>Vila</surname><given-names>M</given-names></name><name name-style="western"><surname>Tieu</surname><given-names>K</given-names></name><name name-style="western"><surname>Teismann</surname><given-names>P</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.</article-title>             <source>J Neurosci</source>             <volume>22</volume>             <fpage>1763</fpage>             <lpage>1771</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Tansey2">
        <label>119</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Tansey</surname><given-names>MG</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>MK</given-names></name><name name-style="western"><surname>Frank-Cannon</surname><given-names>TC</given-names></name></person-group>             <year>2007</year>             <article-title>Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.</article-title>             <source>Exp Neurol</source>             <volume>208</volume>             <fpage>1</fpage>             <lpage>25</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Krzyszton1">
        <label>120</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Krzyszton</surname><given-names>CP</given-names></name><name name-style="western"><surname>Sparkman</surname><given-names>NL</given-names></name><name name-style="western"><surname>Grant</surname><given-names>RW</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>JB</given-names></name><name name-style="western"><surname>Broussard</surname><given-names>SR</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Exacerbated fatigue and motor deficits in interleukin-10-deficient mice after peripheral immune stimulation.</article-title>             <source>Am J Physiol Regul Integr Comp Physiol</source>             <volume>295</volume>             <fpage>R1109</fpage>             <lpage>1114</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Lin1">
        <label>121</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>ST</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Feng</surname><given-names>DC</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Tetrandrine suppresses LPS-induced astrocyte activation via modulating IKKs-IkappaBalpha-NF-kappaB signaling pathway.</article-title>             <source>Mol Cell Biochem</source>             <volume>315</volume>             <fpage>41</fpage>             <lpage>49</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-FrankCannon1">
        <label>122</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Frank-Cannon</surname><given-names>TC</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T</given-names></name><name name-style="western"><surname>Ruhn</surname><given-names>KA</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>TN</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Parkin deficiency increases vulnerability to inflammation-related nigral degeneration.</article-title>             <source>J Neurosci</source>             <volume>28</volume>             <fpage>10825</fpage>             <lpage>10834</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Mattson1">
        <label>123</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mattson</surname><given-names>MP</given-names></name><name name-style="western"><surname>Meffert</surname><given-names>MK</given-names></name></person-group>             <year>2006</year>             <article-title>Roles for NF-kappaB in nerve cell survival, plasticity, and disease.</article-title>             <source>Cell Death Differ</source>             <volume>13</volume>             <fpage>852</fpage>             <lpage>860</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Tamatani1">
        <label>124</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Tamatani</surname><given-names>M</given-names></name><name name-style="western"><surname>Che</surname><given-names>YH</given-names></name><name name-style="western"><surname>Matsuzaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Okado</surname><given-names>H</given-names></name><etal/></person-group>             <year>1999</year>             <article-title>Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons.</article-title>             <source>J Biol Chem</source>             <volume>274</volume>             <fpage>8531</fpage>             <lpage>8538</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Cheng1">
        <label>125</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Christakos</surname><given-names>S</given-names></name><name name-style="western"><surname>Mattson</surname><given-names>MP</given-names></name></person-group>             <year>1994</year>             <article-title>Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis.</article-title>             <source>Neuron</source>             <volume>12</volume>             <fpage>139</fpage>             <lpage>153</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Mattson2">
        <label>126</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mattson</surname><given-names>MP</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Fu</surname><given-names>W</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>K</given-names></name></person-group>             <year>1997</year>             <article-title>Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration.</article-title>             <source>J Neurosci Res</source>             <volume>49</volume>             <fpage>681</fpage>             <lpage>697</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Sha1">
        <label>127</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sha</surname><given-names>D</given-names></name><name name-style="western"><surname>Chin</surname><given-names>LS</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group>             <year>2010</year>             <article-title>Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling.</article-title>             <source>Hum Mol Genet</source>             <volume>19</volume>             <fpage>352</fpage>             <lpage>363</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Ghosh1">
        <label>128</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>A</given-names></name><name name-style="western"><surname>Roy</surname><given-names>A</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Kordower</surname><given-names>JH</given-names></name><name name-style="western"><surname>Mufson</surname><given-names>EJ</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>104</volume>             <fpage>18754</fpage>             <lpage>18759</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Teismann1">
        <label>129</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Teismann</surname><given-names>P</given-names></name><name name-style="western"><surname>Schwaninger</surname><given-names>M</given-names></name><name name-style="western"><surname>Weih</surname><given-names>F</given-names></name><name name-style="western"><surname>Ferger</surname><given-names>B</given-names></name></person-group>             <year>2001</year>             <article-title>Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease.</article-title>             <source>Neuroreport</source>             <volume>12</volume>             <fpage>1049</fpage>             <lpage>1053</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Fridmacher1">
        <label>130</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Fridmacher</surname><given-names>V</given-names></name><name name-style="western"><surname>Kaltschmidt</surname><given-names>B</given-names></name><name name-style="western"><surname>Goudeau</surname><given-names>B</given-names></name><name name-style="western"><surname>Ndiaye</surname><given-names>D</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>FM</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Forebrain-specific neuronal inhibition of nuclear factor-kappaB activity leads to loss of neuroprotection.</article-title>             <source>J Neurosci</source>             <volume>23</volume>             <fpage>9403</fpage>             <lpage>9408</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Turrin1">
        <label>131</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Turrin</surname><given-names>NP</given-names></name><name name-style="western"><surname>Rivest</surname><given-names>S</given-names></name></person-group>             <year>2006</year>             <article-title>Tumor necrosis factor alpha but not interleukin 1 beta mediates neuroprotection in response to acute nitric oxide excitotoxicity.</article-title>             <source>J Neurosci</source>             <volume>26</volume>             <fpage>143</fpage>             <lpage>151</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Marchetti1">
        <label>132</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Marchetti</surname><given-names>L</given-names></name><name name-style="western"><surname>Klein</surname><given-names>M</given-names></name><name name-style="western"><surname>Schlett</surname><given-names>K</given-names></name><name name-style="western"><surname>Pfizenmaier</surname><given-names>K</given-names></name><name name-style="western"><surname>Eisel</surname><given-names>UL</given-names></name></person-group>             <year>2004</year>             <article-title>Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway.</article-title>             <source>J Biol Chem</source>             <volume>279</volume>             <fpage>32869</fpage>             <lpage>32881</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Arnett1">
        <label>133</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Arnett</surname><given-names>HA</given-names></name><name name-style="western"><surname>Mason</surname><given-names>J</given-names></name><name name-style="western"><surname>Marino</surname><given-names>M</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsushima</surname><given-names>GK</given-names></name><etal/></person-group>             <year>2001</year>             <article-title>TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.</article-title>             <source>Nat Neurosci</source>             <volume>4</volume>             <fpage>1116</fpage>             <lpage>1122</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Mason1">
        <label>134</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mason</surname><given-names>JL</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Chaplin</surname><given-names>DD</given-names></name><name name-style="western"><surname>Matsushima</surname><given-names>GK</given-names></name></person-group>             <year>2001</year>             <article-title>Interleukin-1beta promotes repair of the CNS.</article-title>             <source>J Neurosci</source>             <volume>21</volume>             <fpage>7046</fpage>             <lpage>7052</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Cao1">
        <label>135</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>JP</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Yu</surname><given-names>JK</given-names></name><name name-style="western"><surname>Liu</surname><given-names>HM</given-names></name><name name-style="western"><surname>Gao</surname><given-names>DS</given-names></name></person-group>             <year>2008</year>             <article-title>The involvement of NF-kappaB p65/p52 in the effects of GDNF on DA neurons in early PD rats.</article-title>             <source>Brain Res Bull</source>             <volume>76</volume>             <fpage>505</fpage>             <lpage>511</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Sullivan1">
        <label>136</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sullivan</surname><given-names>PG</given-names></name><name name-style="western"><surname>Rabchevsky</surname><given-names>AG</given-names></name><name name-style="western"><surname>Keller</surname><given-names>JN</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>M</given-names></name><name name-style="western"><surname>Sodhi</surname><given-names>A</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Intrinsic differences in brain and spinal cord mitochondria: Implication for therapeutic interventions.</article-title>             <source>J Comp Neurol</source>             <volume>474</volume>             <fpage>524</fpage>             <lpage>534</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Akundi1">
        <label>137</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Akundi</surname><given-names>RS</given-names></name><name name-style="western"><surname>Candelario-Jalil</surname><given-names>E</given-names></name><name name-style="western"><surname>Hess</surname><given-names>S</given-names></name><name name-style="western"><surname>Hull</surname><given-names>M</given-names></name><name name-style="western"><surname>Lieb</surname><given-names>K</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia.</article-title>             <source>Glia</source>             <volume>51</volume>             <fpage>199</fpage>             <lpage>208</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Cass1">
        <label>138</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cass</surname><given-names>WA</given-names></name><name name-style="western"><surname>Harned</surname><given-names>ME</given-names></name><name name-style="western"><surname>Peters</surname><given-names>LE</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A</given-names></name><name name-style="western"><surname>Maragos</surname><given-names>WF</given-names></name></person-group>             <year>2003</year>             <article-title>HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat.</article-title>             <source>Brain Res</source>             <volume>984</volume>             <fpage>133</fpage>             <lpage>142</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Dong1">
        <label>139</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wolfer</surname><given-names>DP</given-names></name><name name-style="western"><surname>Lipp</surname><given-names>HP</given-names></name><name name-style="western"><surname>Bueler</surname><given-names>H</given-names></name></person-group>             <year>2005</year>             <article-title>Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.</article-title>             <source>Mol Ther</source>             <volume>11</volume>             <fpage>80</fpage>             <lpage>88</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Paterna1">
        <label>140</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Paterna</surname><given-names>JC</given-names></name><name name-style="western"><surname>Leng</surname><given-names>A</given-names></name><name name-style="western"><surname>Weber</surname><given-names>E</given-names></name><name name-style="western"><surname>Feldon</surname><given-names>J</given-names></name><name name-style="western"><surname>Bueler</surname><given-names>H</given-names></name></person-group>             <year>2007</year>             <article-title>DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice.</article-title>             <source>Mol Ther</source>             <volume>15</volume>             <fpage>698</fpage>             <lpage>704</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-West1">
        <label>141</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Slomianka</surname><given-names>L</given-names></name><name name-style="western"><surname>Gundersen</surname><given-names>HJ</given-names></name></person-group>             <year>1991</year>             <article-title>Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator.</article-title>             <source>Anat Rec</source>             <volume>231</volume>             <fpage>482</fpage>             <lpage>497</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Harding1">
        <label>142</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Harding</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Halliday</surname><given-names>GM</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>K</given-names></name></person-group>             <year>1994</year>             <article-title>Practical considerations for the use of the optical disector in estimating neuronal number.</article-title>             <source>J Neurosci Methods</source>             <volume>51</volume>             <fpage>83</fpage>             <lpage>89</lpage>          </element-citation>
      </ref>
      <ref id="pone.0016038-Mills1">
        <label>143</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>RD</given-names></name><name name-style="western"><surname>Sim</surname><given-names>CH</given-names></name><name name-style="western"><surname>Mok</surname><given-names>SS</given-names></name><name name-style="western"><surname>Mulhern</surname><given-names>TD</given-names></name><name name-style="western"><surname>Culvenor</surname><given-names>JG</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Biochemical aspects of the neuroprotective mechanism of PTEN-induced kinase-1 (PINK1).</article-title>             <source>J Neurochem</source>             <volume>105</volume>             <fpage>18</fpage>             <lpage>33</lpage>          </element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>